| Year |
Citation |
Score |
| 2020 |
Jaeckle KA, Ballman KV, van den Bent M, Giannini C, Galanis E, Brown PD, Jenkins RB, Cairncross JG, Wick W, Weller M, Aldape KD, Dixon JG, Anderson SK, Cerhan JH, Wefel JS, et al. CODEL: Phase III study of RT, RT + Temozolomide (TMZ), or TMZ for newly-diagnosed 1p/19q Codeleted Oligodendroglioma. Analysis from the initial study design. Neuro-Oncology. PMID 32678879 DOI: 10.1093/Neuonc/Noaa168 |
0.317 |
|
| 2020 |
Vaubel R, Zschernack V, Tran QT, Jenkins S, Caron A, Milosevic D, Smadbeck J, Vasmatzis G, Kandels D, Gnekow A, Kramm C, Jenkins R, Kipp BR, Rodriguez FJ, Orr BA, et al. Biology and grading of pleomorphic xanthoastrocytoma-what have we learned about it? Brain Pathology (Zurich, Switzerland). PMID 32619305 DOI: 10.1111/Bpa.12874 |
0.349 |
|
| 2020 |
Zepeda-Mendoza CJ, Vaubel RA, Zarei S, Ida CM, Matthews M, Acree S, Raghunathan A, Giannini C, Jenkins RB. Concomitant 1p/19q co-deletion and IDH1/2, ATRX, and TP53 mutations within a single clone of "dual-genotype" IDH-mutant infiltrating gliomas. Acta Neuropathologica. PMID 32170402 DOI: 10.1007/S00401-020-02141-X |
0.326 |
|
| 2020 |
Molinaro AM, Hervey-Jumper S, Morshed RA, Young J, Han SJ, Chunduru P, Zhang Y, Phillips JJ, Shai A, Lafontaine M, Crane J, Chandra A, Flanigan P, Jahangiri A, Cioffi G, ... ... Jenkins R, et al. Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. Jama Oncology. PMID 32027343 DOI: 10.1001/Jamaoncol.2019.6143 |
0.337 |
|
| 2020 |
Eckel-Passow JE, Drucker KL, Kollmeyer TM, Kosel ML, Decker PA, Molinaro AM, Rice T, Praska CE, Clark LE, Caron AA, Abyzov A, Batzler A, Song JS, Pekmezci M, Hansen HM, ... ... Jenkins RB, et al. Abstract 1193: Adult diffuse glioma GWAS by molecular subtype identifies variants in D2HGDH, FAM20C and GMEB2 Epidemiology. 80: 1193-1193. DOI: 10.1158/1538-7445.Am2020-1193 |
0.396 |
|
| 2019 |
Vaubel RA, Tian S, Remonde D, Schroeder MA, Mladek AC, Kitange GJ, Caron A, Kollmeyer TM, Grove R, Peng S, Carlson BL, Ma DJ, Sarkar G, Evers L, Decker PA, ... ... Jenkins RB, et al. Genomic and phenotypic characterization of a broad panel of patient derived xenografts reflects the diversity of glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31852831 DOI: 10.1158/1078-0432.Ccr-19-0909 |
0.34 |
|
| 2019 |
Blessing MM, Blackburn PR, Krishnan C, Harrod VL, Barr Fritcher EG, Zysk CD, Jackson RA, Milosevic D, Nair AA, Davila JI, Balcom JR, Jenkins RB, Halling KC, Kipp BR, Nageswara Rao AA, et al. Desmoplastic Infantile Ganglioglioma: A MAPK Pathway-Driven and Microglia/Macrophage-Rich Neuroepithelial Tumor. Journal of Neuropathology and Experimental Neurology. PMID 31562743 DOI: 10.1093/Jnen/Nlz086 |
0.328 |
|
| 2019 |
Johnson DR, Giannini C, Jenkins RB, Kim DK, Kaufmann TJ. Plenty of calcification: imaging characterization of polymorphous low-grade neuroepithelial tumor of the young. Neuroradiology. PMID 31396664 DOI: 10.1007/S00234-019-02269-Y |
0.309 |
|
| 2019 |
Cheng A, Zhao S, FitzGerald LM, Wright JL, Kolb S, Karnes RJ, Jenkins RB, Davicioni E, Ostrander EA, Feng Z, Fan JB, Dai JY, Stanford JL. A four-gene transcript score to predict metastatic-lethal progression in men treated for localized prostate cancer: Development and validation studies. The Prostate. PMID 31376183 DOI: 10.1002/Pros.23882 |
0.335 |
|
| 2019 |
Burgenske DM, Yang J, Decker PA, Kollmeyer TM, Kosel ML, Mladek AC, Caron AA, Vaubel RA, Gupta SK, Kitange GJ, Sicotte H, Youland RS, Remonde D, Voss JS, Fritcher EGB, ... ... Jenkins RB, et al. Molecular Profiling of Long-Term IDH-wildtype Glioblastoma Survivors. Neuro-Oncology. PMID 31346613 DOI: 10.1093/Neuonc/Noz129 |
0.308 |
|
| 2019 |
Horbinski C, Ligon KL, Brastianos P, Huse JT, Venere M, Chang S, Buckner J, Cloughesy T, Jenkins RB, Giannini C, Nabors LB, Wen PY, Aldape KJ, Lukas RV, Galanis E, et al. The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology. PMID 31276167 DOI: 10.1093/Neuonc/Noz119 |
0.337 |
|
| 2019 |
Jaeckle KA, Anderson SK, Twohy EL, Dixon JG, Giannini C, Jenkins R, Egorin MJ, Sarkaria JN, Brown PD, Flynn PJ, Schwerkoske J, Buckner JC, Galanis E. Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North central cancer treatment group study N0272 (ALLIANCE/NCCTG). Journal of Neuro-Oncology. PMID 31119479 DOI: 10.1007/S11060-019-03194-Z |
0.326 |
|
| 2019 |
Ostrom QT, Egan KM, Nabors LB, Gerke T, Thompson RC, Olson JJ, La Rocca R, Chowdhary S, Eckel-Passow JE, Armstrong G, Wiencke JK, Bernstein JL, Claus EB, Il'yasova D, Johansen C, ... ... Jenkins RB, et al. Glioma risk associated with extent of estimated European genetic ancestry in African-Americans and Hispanics. International Journal of Cancer. PMID 30963577 DOI: 10.1002/Ijc.32318 |
0.359 |
|
| 2019 |
Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, Sun S, Kuznik NC, Göppert B, Ozgun F, van Royen ME, ... ... Jenkins RB, et al. ARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer. Cancer Cell. PMID 30773341 DOI: 10.1016/J.Ccell.2019.01.008 |
0.344 |
|
| 2019 |
Blackburn PR, Davila JI, Jackson RA, Fadra N, Atiq MA, Pitel BA, Nair AA, Van De Walker TJ, Hessler MG, Hovel SK, Wehrs RN, Fritchie KJ, Jenkins RB, Halling KC, Geiersbach KB. RNA sequencing identifies a novel USP9X-USP6 promoter swap gene fusion in a primary aneurysmal bone cyst. Genes, Chromosomes & Cancer. PMID 30767316 DOI: 10.1002/Gcc.22742 |
0.327 |
|
| 2019 |
Atkins I, Kinnersley B, Ostrom QT, Labreche K, Il'yasova D, Armstrong GN, Eckel-Passow JE, Schoemaker MJ, Nöthen MM, Barnholtz-Sloan JS, Swerdlow AJ, Simon M, Rajaraman P, Chanock SJ, Shildkraut J, ... ... Jenkins RB, et al. Transcriptome-wide association study identifies new candidate susceptibility genes for glioma. Cancer Research. PMID 30709929 DOI: 10.1158/0008-5472.Can-18-2888 |
0.369 |
|
| 2019 |
Beckmann PJ, Larson JD, Larsson AT, Ostergaard JP, Wagner S, Rahrmann EP, Shamsan GA, Otto GM, Williams RL, Wang J, Lee C, Tschida BR, Das P, Dubuc AM, Moriarity BS, ... ... Jenkins RB, et al. Sleeping Beauty insertional mutagenesis reveals important genetic drivers of central nervous system embryonal tumors. Cancer Research. PMID 30674530 DOI: 10.1158/0008-5472.Can-18-1261 |
0.327 |
|
| 2019 |
Ostrom QT, Armstrong G, Amos CI, Bernstein JL, Claus EB, Eckel-Passow JE, Il'yasova D, Johansen C, Lachance DH, Lai RK, Merrell RT, Olson SH, Schildkraut JH, Shete SS, Houlston RS, ... Jenkins RB, et al. Abstract 4173: Previously identified common glioma risk SNPs are associated with familial glioma Cancer Research. 79: 4173-4173. DOI: 10.1158/1538-7445.Am2019-4173 |
0.314 |
|
| 2019 |
Ida C, Johnson D, Kollmeyer T, Kim D, Kaufmann T, Kipp B, Jenkins R, Giannini C. Rare-32. Polymorphous Low-Grade Neuroepithelial Tumor Of The Young (Plnty): Genetic Analysis Confirms Frequent Mapk Pathway Activation Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.955 |
0.324 |
|
| 2019 |
Brown D, Yamada S, Kollmeyer T, Decker P, Kosel M, Praska C, Raghunathan A, Giannini C, Lachance D, Eckel-Passow J, Jenkins R. GENE-29. INCREASED COPY NUMBER BURDEN (CNB) IS ASSOCIATED WITH GRADE IN IDH-MUTANT, 1p/19q-CODELETED OLIGODENDROGLIOMAS. Neuro-Oncology. 21: vi103-vi104. DOI: 10.1093/Neuonc/Noz175.431 |
0.397 |
|
| 2018 |
Aypar U, Smoley SA, Pitel BA, Pearce KE, Zenka RM, Vasmatzis G, Johnson SH, Smadbeck JB, Peterson JF, Geiersbach KB, Van Dyke DL, Thorland EC, Jenkins RB, Ketterling RP, Greipp PT, et al. Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia. European Journal of Haematology. PMID 30270457 DOI: 10.1111/Ejh.13179 |
0.339 |
|
| 2018 |
Brat DJ, Aldape K, Colman H, Holland EC, Louis DN, Jenkins RB, Kleinschmidt-DeMasters BK, Perry A, Reifenberger G, Stupp R, von Deimling A, Weller M. cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". Acta Neuropathologica. PMID 30259105 DOI: 10.1007/S00401-018-1913-0 |
0.326 |
|
| 2018 |
Ostrom QT, Kinnersley B, Armstrong G, Rice T, Chen Y, Wiencke JK, McCoy LS, Hansen HM, Amos CI, Bernstein JL, Claus EB, Eckel-Passow JE, Il'yasova D, Johansen C, Lachance DH, ... ... Jenkins RB, et al. Age-specific genome-wide association study in glioblastoma identifies increased proportion of 'lower grade glioma'-like features associated with younger age. International Journal of Cancer. PMID 30152087 DOI: 10.1002/Ijc.31759 |
0.345 |
|
| 2018 |
Rounbehler RJ, Berglund AE, Gerke T, Takhar MM, Awasthi S, Li W, Davicioni E, Erho NG, Ross AE, Schaeffer EM, Klein EA, Karnes RJ, Jenkins RB, Cleveland JL, Park JY, et al. Tristetraprolin Is a Prognostic Biomarker for Poor Outcomes among Patients with Low-Grade Prostate Cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 30108099 DOI: 10.1158/1055-9965.Epi-18-0369 |
0.341 |
|
| 2018 |
Winters JL, Davila JI, McDonald AM, Nair AA, Fadra N, Wehrs RN, Thomas BC, Balcom JR, Jin L, Wu X, Voss JS, Klee EW, Oliver GR, Graham RP, Neff JL, ... ... Jenkins RB, et al. Development and Verification of an RNA Sequencing (RNA-Seq) Assay for the Detection of Gene Fusions in Tumors. The Journal of Molecular Diagnostics : Jmd. PMID 29929942 DOI: 10.1016/J.Jmoldx.2018.03.007 |
0.303 |
|
| 2018 |
Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018778738. PMID 29846122 DOI: 10.1200/Jco.2018.77.8738 |
0.329 |
|
| 2018 |
Alshalalfa M, Karnes RJ, Sharma V, Choeurng V, Al-Deen Ashab H, Erho N, Trock BJ, Ross AE, Yousefi K, Tsai HK, Zhao SG, Tosoian JJ, Haddad Z, Takhar M, Chang SL, ... ... Jenkins RB, et al. Development and validation of a prostate cancer genomic signature that predicts early ADT treatment response following radical prostatectomy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29760221 DOI: 10.1158/1078-0432.Ccr-17-2745 |
0.312 |
|
| 2018 |
Ostrom QT, Kinnersley B, Wrensch MR, Eckel-Passow JE, Armstrong G, Rice T, Chen Y, Wiencke JK, McCoy LS, Hansen HM, Amos CI, Bernstein JL, Claus EB, Il'yasova D, Johansen C, ... ... Jenkins RB, et al. Sex-specific glioma genome-wide association study identifies new risk locus at 3p21.31 in females, and finds sex-differences in risk at 8q24.21. Scientific Reports. 8: 7352. PMID 29743610 DOI: 10.1038/S41598-018-24580-Z |
0.319 |
|
| 2018 |
Johnson SH, Smadbeck JB, Smoley SA, Gaitatzes A, Murphy SJ, Harris FR, Drucker TM, Zenka RM, Pitel BA, Rowsey RA, Hoppman NL, Aypar U, Sukov WR, Jenkins RB, Feldman AL, et al. SVAtools for junction detection of genome-wide chromosomal rearrangements by mate-pair sequencing (MPseq). Cancer Genetics. 221: 1-18. PMID 29405991 DOI: 10.1016/J.Cancergen.2017.11.009 |
0.316 |
|
| 2018 |
Kosel M, Lachance D, Decker P, Kollmeyer T, Caron A, Drucker K, Sarkar G, Knight A, Halder C, Tian S, Abyzov A, Burns T, Giannini C, Eckel-Passow J, Jenkins R. GENE-29. DLL3 AND ETV1 ARE INACTIVATED/METHYLATED IN CIC WILD-TYPE, IDH-MUTATED, 1p/19q-CODELETED GLIOMA Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy148.455 |
0.316 |
|
| 2018 |
Ostrom Q, Armstrong G, Amos C, Bernstein J, Claus E, Eckel-Passow J, Il’yasova D, Johansen C, Lachance D, Lai R, Merrell R, Olson S, Schildkraut J, Shete S, Houlston R, ... Jenkins R, et al. GENE-23. PREVIOUSLY IDENTIFIED COMMON GLIOMA RISK SNPs ARE ASSOCIATED WITH FAMILIAL GLIOMA Neuro-Oncology. 20: vi108-vi108. DOI: 10.1093/Neuonc/Noy148.449 |
0.319 |
|
| 2018 |
Brown D, Yamada S, Praska C, Kollmeyer T, Jacobs J, Decker P, Kosel M, Caron A, Halder C, Ruiz V, Kipp B, Voss J, Vaubel R, Giannini C, Jenkins R. GENE-11. SMALL TERMINAL ALTERATIONS AND ALTERNATIVE LENGTHENING OF TELOMERES ARE A FEATURE OF IDH-MUTANT, 1p/19q NON-CODELETED GLIOMAS Neuro-Oncology. 20: vi105-vi105. DOI: 10.1093/Neuonc/Noy148.438 |
0.344 |
|
| 2018 |
Baughn LB, Smoley SA, Aypar U, Pitel BA, Vasmatzis G, Johnson SH, Smadbeck JB, Peterson JF, Geiersbach KB, Dyke DLV, Thorland EC, Ketterling RP, Jenkins RB, Hoppman NL, Kearney HM, et al. 13. Clinical utility of mate pair sequencing to detect diagnostic and prognostic chromosomal rearrangements and copy number changes in patients with acute myeloid leukemia Cancer Genetics and Cytogenetics. 36. DOI: 10.1016/J.Cancergen.2018.04.016 |
0.317 |
|
| 2017 |
Sharma V, Yousefi K, Haddad Z, Buerki C, Jenkins RB, Davicioni E, Karnes RJ. Gene Expression Correlates of Site-Specific Metastasis among Men with Lymph Node Positive Prostate Cancer Treated with Radical Prostatectomy: a Case Series. Urology. PMID 29079212 DOI: 10.1016/J.Urology.2017.10.016 |
0.322 |
|
| 2017 |
Ruiz VY, Praska CE, Armstrong G, Kollmeyer TM, Yamada S, Decker PA, Kosel ML, Eckel-Passow JE, Consortium TG, Lachance DH, Bainbridge MN, Melin BS, Bondy ML, Jenkins RB. Molecular Subtyping of Tumors from Patients with Familial Glioma. Neuro-Oncology. PMID 29040662 DOI: 10.1093/Neuonc/Nox192 |
0.326 |
|
| 2017 |
Takami H, Graffeo C, Perry A, Raghunathan A, Jenkins RB, Giannini C, Burns TC. Giant Cell Ependymoma of the Lateral Ventricle: Case Report, Literature Review, and Analysis of Prognostic Factors and Genetic Profile. World Neurosurgery. PMID 28943417 DOI: 10.1016/J.Wneu.2017.09.088 |
0.346 |
|
| 2017 |
Labbé DP, Sweeney CJ, Brown M, Galbo P, Rosario S, Wadosky KM, Ku SY, Sjöström M, Alshalalfa M, Erho N, Davicioni E, Karnes RJ, Schaeffer EM, Jenkins RB, Den RB, et al. TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28899973 DOI: 10.1158/1078-0432.Ccr-17-0413 |
0.332 |
|
| 2017 |
van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, ... ... Jenkins RB, et al. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet (London, England). PMID 28801186 DOI: 10.1016/S0140-6736(17)31442-3 |
0.372 |
|
| 2017 |
Vaubel RA, Kollmeyer TM, Caron AA, Barr Fritcher EG, Voss JS, Liang H, Jenkins RB, Giannini C, Kipp BR. Synchronous gemistocytic astrocytoma IDH-mutant and oligodendroglioma IDH-mutant and 1p/19q-codeleted in a patient with CCDC26 polymorphism. Acta Neuropathologica. PMID 28550371 DOI: 10.1007/S00401-017-1727-5 |
0.319 |
|
| 2017 |
Reinholz MM, Chen B, Dueck AC, Tenner K, Ballman K, Riehle D, Jenkins RB, Geiger XJ, McCullough AE, Perez EA. IGF1R Protein Expression Is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2(+) Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28533226 DOI: 10.1158/1078-0432.Ccr-15-0574 |
0.398 |
|
| 2017 |
Buckner J, Giannini C, Eckel-Passow J, Lachance D, Parney I, Laack N, Jenkins R. Management of diffuse low-grade gliomas in adults - use of molecular diagnostics. Nature Reviews. Neurology. PMID 28497806 DOI: 10.1038/Nrneurol.2017.54 |
0.381 |
|
| 2017 |
Zhao SG, Chang SL, Erho N, Yu M, Lehrer J, Alshalalfa M, Speers C, Cooperberg MR, Kim W, Ryan CJ, Den RB, Freedland SJ, Posadas E, Sandler H, Klein EA, ... ... Jenkins RB, et al. Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. Jama Oncology. PMID 28494073 DOI: 10.1001/Jamaoncol.2017.0751 |
0.307 |
|
| 2017 |
Bryce AH, Egan JB, Borad MJ, Stewart AK, Nowakowski GS, Chanan-Khan A, Patnaik MM, Ansell SM, Banck MS, Robinson SI, Mansfield AS, Klee EW, Oliver GR, McCormick JB, Huneke NE, ... ... Jenkins RB, et al. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. Oncotarget. 27145-27154. PMID 28423702 DOI: 10.18632/Oncotarget.16057 |
0.306 |
|
| 2017 |
Holdhoff M, Cairncross GJ, Kollmeyer TM, Zhang M, Zhang P, Mehta MP, Werner-Wasik M, Souhami L, Bahary JP, Kwok Y, Hartford AC, Chakravarti A, Yegnasubramanian S, Vogelstein B, Papadopoulos N, ... ... Jenkins RB, et al. Genetic landscape of extreme responders with anaplastic oligodendroglioma. Oncotarget. PMID 28388591 DOI: 10.18632/Oncotarget.16773 |
0.354 |
|
| 2017 |
Melin BS, Barnholtz-Sloan JS, Wrensch MR, Johansen C, Il'yasova D, Kinnersley B, Ostrom QT, Labreche K, Chen Y, Armstrong G, Liu Y, Eckel-Passow JE, Decker PA, Labussière M, Idbaih A, ... ... Jenkins RB, et al. Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nature Genetics. PMID 28346443 DOI: 10.1038/Ng.3823 |
0.334 |
|
| 2017 |
Pekmezci M, Rice T, Molinaro AM, Walsh KM, Decker PA, Hansen H, Sicotte H, Kollmeyer TM, McCoy LS, Sarkar G, Perry A, Giannini C, Tihan T, Berger MS, Wiemels JL, ... ... Jenkins RB, et al. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathologica. PMID 28255664 DOI: 10.1007/S00401-017-1690-1 |
0.379 |
|
| 2017 |
Vaubel RA, Caron AA, Yamada S, Decker PA, Eckel Passow JE, Rodriguez FJ, Nageswara Rao AA, Lachance D, Parney I, Jenkins R, Giannini C. Recurrent copy number alterations in low-grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation. Brain Pathology (Zurich, Switzerland). PMID 28181325 DOI: 10.1111/Bpa.12495 |
0.392 |
|
| 2017 |
Nouri M, Caradec J, Lubik AA, Li N, Hollier BG, Takhar M, Altimirano-Dimas M, Chen M, Roshan-Moniri M, Butler M, Lehman M, Bishop J, Truong S, Huang SC, Cochrane D, ... ... Jenkins RB, et al. Therapy-induced developmental reprogramming of prostate cancer cells and acquired therapy resistance. Oncotarget. PMID 28145883 DOI: 10.18632/Oncotarget.14850 |
0.314 |
|
| 2017 |
Johnson DR, Diehn FE, Giannini C, Jenkins RB, Jenkins SM, Parney IF, Kaufmann TJ. Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI. Ajnr. American Journal of Neuroradiology. PMID 28126746 DOI: 10.3174/Ajnr.A5070 |
0.342 |
|
| 2017 |
Pellegrini KL, Sanda MG, Patil D, Long Q, Santiago-Jiménez M, Takhar M, Erho N, Yousefi K, Davicioni E, Klein EA, Jenkins RB, Karnes RJ, Moreno CS. Evaluation of a 24-Gene Signature for Prognosis of Metastatic Events and Prostate Cancer-Specific Mortality. Bju International. PMID 28107602 DOI: 10.1111/Bju.13779 |
0.32 |
|
| 2017 |
Tse BW, Volpert M, Ratther E, Stylianou N, Nouri M, McGowan K, Lehman ML, McPherson SJ, Roshan-Moniri M, Butler MS, Caradec J, Gregory-Evans CY, McGovern J, Das R, Takhar M, ... ... Jenkins RB, et al. Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. Oncogene. PMID 28092670 DOI: 10.1038/Onc.2016.482 |
0.381 |
|
| 2017 |
Volpert M, Tse B, Ratther E, Stylianou N, Nouri M, Lehman M, McPherson S, Roshan-Moniri M, Takhar M, Erho N, Alshalafa M, Davicioni E, Jenkins R, Ross A, Karnes J, et al. Abstract 4908: Neuropilin-1 is up-regulated in the adaptive response of prostate tumors to androgen targeted therapies and is prognostic of metastatic progression and patient mortality Cancer Research. 77: 4908-4908. DOI: 10.1158/1538-7445.Am2017-4908 |
0.356 |
|
| 2017 |
Brown DA, Yamada S, Kollmeyer T, Decker P, Kosel ML, Sarkar G, Caron A, Halder C, Ruiz VY, Kipp BR, Voss JS, Giannini C, Jenkins R. 156 Small Terminal Deletions/Duplications and Alternative Lengthening of Telomeres are Co-Occur in IDH Mutation Only Gliomas Neurosurgery. 64: 238-239. DOI: 10.1093/Neuros/Nyx417.156 |
0.391 |
|
| 2016 |
Klein EA, Santiago-Jiménez M, Yousefi K, Robbins BA, Schaeffer EM, Trock BJ, Tosoian J, Haddad Z, Ra S, Karnes RJ, Jenkins RB, Cheville JC, Den RB, Dicker AP, Davicioni E, et al. Molecular analysis of low grade prostate cancer utilizing a genomic classifier of metastatic potential. The Journal of Urology. PMID 27569435 DOI: 10.1016/J.Juro.2016.08.091 |
0.358 |
|
| 2016 |
Hu LS, Ning S, Eschbacher JM, Baxter LC, Gaw N, Ranjbar S, Plasencia J, Dueck AC, Peng S, Smith KA, Nakaji P, Karis JP, Quarles CC, Wu T, Loftus JC, ... Jenkins RB, et al. Radiogenomics to characterize regional genetic heterogeneity in glioblastoma. Neuro-Oncology. PMID 27502248 DOI: 10.1093/Neuonc/Now135 |
0.301 |
|
| 2016 |
Yoon HH, Lewis MA, Foster NR, Sukov WR, Khan M, Sattler CA, Wiktor AE, Wu TT, Jenkins RB, Sinicrope FA. Central nervous system relapse in patients with untreated her2-positive esophageal or gastroesophageal junction adenocarcinoma. International Journal of Cancer. PMID 27198655 DOI: 10.1002/Ijc.30200 |
0.375 |
|
| 2016 |
Guo R, Wang X, Chou MM, Yan A, Wenger DE, Al-Ibraheemi A, Molavi DW, Aboulafia A, Jin L, Fritchie K, Oliveira JL, Jenkins RB, Westendorf JJ, Dong J, Oliveira AM. PPP6R3-USP6 Amplification: Novel Oncogenic Mechanism in Malignant Nodular Fasciitis. Genes, Chromosomes & Cancer. PMID 27113271 DOI: 10.1002/Gcc.22366 |
0.301 |
|
| 2016 |
Trock BJ, Fedor H, Gurel B, Jenkins RB, Knudsen BS, Fine SW, Said JW, Carter HB, Lotan TL, De Marzo AM. PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 27080984 DOI: 10.1038/Modpathol.2016.63 |
0.399 |
|
| 2016 |
Rice T, Lachance DH, Molinaro AM, Eckel-Passow JE, Walsh KM, Barnholtz-Sloan J, Ostrom QT, Francis SS, Wiemels J, Jenkins RB, Wiencke JK, Wrensch MR. Understanding inherited genetic risk of adult glioma - a review. Neuro-Oncology Practice. 3: 10-16. PMID 26941959 DOI: 10.1093/Nop/Npv026 |
0.332 |
|
| 2016 |
Hu BR, Fairey AS, Madhav A, Yang D, Li M, Groshen S, Stephens C, Kim PH, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins RB, Den RB, et al. AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth. The Prostate. PMID 26771938 DOI: 10.1002/Pros.23151 |
0.357 |
|
| 2016 |
Karnes J, Ashab HA, Trock BJ, Ross A, Tsai H, Tosoian JJ, Erho N, Choeurng V, Yousefi K, Haddad Z, Abdollah F, Klein EA, Nguyen PL, Feng FY, Dicker A, ... ... Jenkins RB, et al. Development and validation of an ADT resistance signature to predict adjuvant hormone treatment failure. Journal of Clinical Oncology. 34: 106-106. DOI: 10.1200/Jco.2016.34.2_Suppl.106 |
0.35 |
|
| 2016 |
Holdhoff M, Cairncross JG, Jenkins RB, Bettegowda C, Zhang M, Kollmeyer TM, Yegnasubramanian ST, Grossman SA, Vogelstein B, Papadopoulos N, Kinzler KW, Werner-Wasik M, Souhami L, Bahary J, Kwok Y, et al. Genetic landscape of extreme responders with anaplastic oligodendroglioma: NRG Oncology/RTOG 9402. Journal of Clinical Oncology. 34: 2054-2054. DOI: 10.1200/Jco.2016.34.15_Suppl.2054 |
0.376 |
|
| 2016 |
Lai RK, Zhou R, Amirian ES, Johansen C, Scheurer ME, Armstrong GN, Lau CC, Claus EB, Barnholtz-Sloan JS, Il’yasova D, Schildkraut J, Ali-Osman F, Sadetzki S, Houlston R, Jenkins RB, et al. Abstract 3446: Aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) and the risk of glioma: Results from the Glioma International Case Control Study Cancer Research. 76: 3446-3446. DOI: 10.1158/1538-7445.Am2016-3446 |
0.317 |
|
| 2016 |
Ruiz V, Armstrong G, Praska C, Kollmeyer T, Yamada S, Decker P, Kosel M, Eckel-Passow J, Lachance D, Bainbridge M, Melin B, Bondy M, Jenkins R. GENT-12. MOLECULAR GROUPING OF TUMORS FROM PATIENTS WITH FAMILIAL GLIOMA Neuro-Oncology. 18: vi76-vi76. DOI: 10.1093/Neuonc/Now212.318 |
0.313 |
|
| 2016 |
Rowsey RA, Greipp PT, Jenkins RB, Kearney HM. Interpreting Complex SNP-Array Results in Tumors: Clues Invoking Classical Cytogenetic Mechanisms Cancer Genetics. 209: 234. DOI: 10.1016/J.Cancergen.2016.05.015 |
0.314 |
|
| 2015 |
Amirian ES, Armstrong GN, Zhou R, Lau CC, Claus EB, Barnholtz-Sloan JS, Il'yasova D, Schildkraut J, Ali-Osman F, Sadetzki S, Johansen C, Houlston RS, Jenkins RB, Lachance D, Olson SH, et al. The Glioma International Case-Control Study: A Report From the Genetic Epidemiology of Glioma International Consortium. American Journal of Epidemiology. PMID 26656478 DOI: 10.1093/Aje/Kwv235 |
0.323 |
|
| 2015 |
Walsh KM, Codd V, Rice T, Nelson CP, Smirnov IV, McCoy LS, Hansen HM, Elhauge E, Ojha J, Francis SS, Madsen NR, Bracci PM, Pico AR, Molinaro AM, Tihan T, ... ... Jenkins RB, et al. Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. Oncotarget. PMID 26646793 DOI: 10.18632/Oncotarget.6468 |
0.317 |
|
| 2015 |
Hu LS, Ning S, Eschbacher JM, Gaw N, Dueck AC, Smith KA, Nakaji P, Plasencia J, Ranjbar S, Price SJ, Tran N, Loftus J, Jenkins R, O'Neill BP, Elmquist W, et al. Multi-Parametric MRI and Texture Analysis to Visualize Spatial Histologic Heterogeneity and Tumor Extent in Glioblastoma. Plos One. 10: e0141506. PMID 26599106 DOI: 10.1371/Journal.Pone.0141506 |
0.328 |
|
| 2015 |
Walsh KM, de Smith AJ, Hansen HM, Smirnov IV, Gonseth S, Endicott AA, Xiao J, Rice T, Fu CH, McCoy LS, Lachance DH, Eckel-Passow JE, Wiencke JK, Jenkins RB, Wrensch MR, et al. A Heritable Missense Polymorphism in CDKN2A Confers Strong Risk of Childhood Acute Lymphoblastic Leukemia and Is Preferentially Selected during Clonal Evolution. Cancer Research. PMID 26527286 DOI: 10.1158/0008-5472.Can-15-1105 |
0.338 |
|
| 2015 |
Leeper HE, Caron AA, Decker PA, Jenkins RB, Lachance DH, Giannini C. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Oncotarget. 6: 30295-305. PMID 26210286 DOI: 10.18632/Oncotarget.4497 |
0.381 |
|
| 2015 |
Vogelbaum MA, Hu C, Peereboom DM, Macdonald DR, Giannini C, Suh JH, Jenkins RB, Laack NN, Brachman DG, Shrieve DC, Souhami L, Mehta MP. Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: long term results of RTOG BR0131. Journal of Neuro-Oncology. PMID 26088460 DOI: 10.1007/S11060-015-1845-7 |
0.359 |
|
| 2015 |
Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, ... ... Jenkins RB, et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. The New England Journal of Medicine. 372: 2499-508. PMID 26061753 DOI: 10.1056/Nejmoa1407279 |
0.394 |
|
| 2015 |
Walsh KM, Wiencke JK, Lachance DH, Wiemels JL, Molinaro AM, Eckel-Passow JE, Jenkins RB, Wrensch MR. Telomere maintenance and the etiology of adult glioma. Neuro-Oncology. 17: 1445-52. PMID 26014050 DOI: 10.1093/Neuonc/Nov082 |
0.357 |
|
| 2015 |
Zhao SG, Jackson WC, Kothari V, Schipper MJ, Erho N, Evans JR, Speers C, Hamstra DA, Niknafs YS, Nguyen PL, Schaeffer EM, Ross AE, Den RB, Klein EA, Jenkins RB, et al. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 25986914 DOI: 10.1016/J.Ijrobp.2015.07.339 |
0.327 |
|
| 2015 |
Tomlins SA, Alshalalfa M, Davicioni E, Erho N, Yousefi K, Zhao S, Haddad Z, Den RB, Dicker AP, Trock BJ, DeMarzo AM, Ross AE, Schaeffer EM, Klein EA, Magi-Galluzzi C, ... ... Jenkins RB, et al. Characterization of 1577 Primary Prostate Cancers Reveals Novel Biological and Clinicopathologic Insights into Molecular Subtypes. European Urology. PMID 25964175 DOI: 10.1016/J.Eururo.2015.04.033 |
0.327 |
|
| 2015 |
Lobo JM, Dicker AP, Buerki C, Daviconi E, Karnes RJ, Jenkins RB, Patel N, Den RB, Showalter TN. Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis. Plos One. 10: e0116866. PMID 25837660 DOI: 10.1371/Journal.Pone.0116866 |
0.322 |
|
| 2015 |
Jalali A, Amirian ES, Bainbridge MN, Armstrong GN, Liu Y, Tsavachidis S, Jhangiani SN, Plon SE, Lau CC, Claus EB, Barnholtz-Sloan JS, Il'yasova D, Schildkraut J, Ali-Osman F, Sadetzki S, ... ... Jenkins RB, et al. Targeted sequencing in chromosome 17q linkage region identifies familial glioma candidates in the Gliogene Consortium. Scientific Reports. 5: 8278. PMID 25652157 DOI: 10.1038/Srep08278 |
0.382 |
|
| 2015 |
Perez EA, Thompson EA, Ballman KV, Anderson SK, Asmann YW, Kalari KR, Eckel-Passow JE, Dueck AC, Tenner KS, Jen J, Fan JB, Geiger XJ, McCullough AE, Chen B, Jenkins RB, et al. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 701-8. PMID 25605861 DOI: 10.1200/Jco.2014.57.6298 |
0.316 |
|
| 2015 |
Claus EB, Walsh KM, Wiencke JK, Molinaro AM, Wiemels JL, Schildkraut JM, Bondy ML, Berger M, Jenkins R, Wrensch M. Survival and low-grade glioma: the emergence of genetic information. Neurosurgical Focus. 38: E6. PMID 25552286 DOI: 10.3171/2014.10.Focus12367 |
0.359 |
|
| 2015 |
Bainbridge MN, Armstrong GN, Gramatges MM, Bertuch AA, Jhangiani SN, Doddapaneni H, Lewis L, Tombrello J, Tsavachidis S, Liu Y, Jalali A, Plon SE, Lau CC, Parsons DW, Claus EB, ... ... Jenkins RB, et al. Germline mutations in shelterin complex genes are associated with familial glioma. Journal of the National Cancer Institute. 107: 384. PMID 25482530 DOI: 10.1093/Jnci/Dju384 |
0.3 |
|
| 2015 |
Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. European Urology. 67: 326-33. PMID 24998118 DOI: 10.1016/J.Eururo.2014.05.039 |
0.308 |
|
| 2015 |
Feng FY, Tomlins S, Alshalalfa M, Erho N, Yousefi K, Zhao S, Den RB, Dicker A, Schaeffer EM, Klein EA, Magi-Galluzzi C, Karnes RJ, Jenkins RB, Trock BJ, Demarzo A, et al. Molecular and clinical characterization of 1,577 primary prostate cancer tumors to reveal novel clinical and biological insights into its subtypes. Journal of Clinical Oncology. 33: 9-9. DOI: 10.1200/Jco.2015.33.7_Suppl.9 |
0.378 |
|
| 2015 |
Feng FY, Zhao S, Prensner J, Erho N, Schipper MJ, Shi Y, Magi-Galluzzi C, Siddiqui J, Davicioni E, Den RB, Dicker A, Karnes RJ, Wei JT, Klein EA, Jenkins RB, et al. Investigating the long noncoding RNA SChLAP1 as a prognostic tissue and urine biomarker in prostate cancer. Journal of Clinical Oncology. 33: 7-7. DOI: 10.1200/Jco.2015.33.7_Suppl.7 |
0.37 |
|
| 2015 |
Hu BR, Fairey AS, Madhav A, Yang D, Li M, Groshen SG, Stephens C, Kim P, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins RB, Den RB, et al. Effect of AXIN2 expression on prostate cancer recurrence and an invasive, tumorigenic phenotype. Journal of Clinical Oncology. 33: 29-29. DOI: 10.1200/Jco.2015.33.7_Suppl.29 |
0.368 |
|
| 2015 |
Yoon HH, Shi Q, Sukov WR, Sattler CA, Wiktor AE, Diasio RB, Wu T, Jenkins RB, Sinicrope FA. Comparison of HER2 gene amplification (AMP) in primary esophageal and gastroesophageal junction adenocarcinomas (EAC) and their metastatic regional lymph nodes (MLNs). Journal of Clinical Oncology. 33: 4059-4059. DOI: 10.1200/Jco.2015.33.15_Suppl.4059 |
0.366 |
|
| 2015 |
Alshalalfa M, Tomlins SA, Erho N, Yousefi K, Zhao S, Den RB, Dicker AP, Trock B, DeMarzo A, Schaeffer EM, Ross A, Klein EA, Magi-Galluzzi C, Karnes JR, Jenkins RB, et al. Abstract A1-64: Molecular and clinical characterization of 1,577 primary prostate cancer tumors reveals novel clinical and biological insights into its subtypes Cancer Research. 75. DOI: 10.1158/1538-7445.Transcagen-A1-64 |
0.38 |
|
| 2015 |
Remonde DA, Carlson BL, Schroeder MA, Armstrong B, Peng S, Evers L, Decker PA, Passow JE, Berens ME, Tran NL, Jenkins RB, Sarkaria JN. Abstract 1468: Characterization of patient-derived xenograft (PDX) models to evaluate clinical and therapeutic responses of glioblastoma multiforme Cancer Research. 75: 1468-1468. DOI: 10.1158/1538-7445.Am2015-1468 |
0.401 |
|
| 2015 |
Youland R, Remonde D, Caron A, Mladek A, Decker P, Sicotte H, Lachance D, Kipp B, Eckel-Passow J, Huse J, Giannini C, Jenkins R, Sarkaria J. GENO-37MOLECULAR PROFILING OF LONG-TERM SURVIVORS OF GLIOBLASTOMA Neuro-Oncology. 17: v100-v100. DOI: 10.1093/Neuonc/Nov215.37 |
0.346 |
|
| 2015 |
Walsh K, Pekmezci M, Decker P, Hansen H, Sicotte H, Rice T, Kollmeyer T, McCoy L, Sarkar G, Perry A, Giannini C, Tihan T, Berger M, Molinaro A, Wiemels J, ... ... Jenkins R, et al. EPID-31ATRX AND TERT ASSAYS PROVIDE NON-REDUNDANT INFORMATION IN ADULT GLIOMA PATIENTS: INCORPORATING TELOMERE MARKERS INTO NEUROPATHOLOGY PRACTICE Neuro-Oncology. 17: v85.1-v85. DOI: 10.1093/Neuonc/Nov213.31 |
0.391 |
|
| 2015 |
Rice T, Lachance D, Molinaro A, Eckel-Passow J, Walsh K, Barnholtz-Sloan J, Ostrum Q, Francis S, Wiemels J, Jenkins R, Wiencke J, Wrensch M. EPID-23UNDERSTANDING INHERITED GENETIC RISK OF ADULT GLIOMA - A REVIEW Neuro-Oncology. 17: v83.1-v83. DOI: 10.1093/Neuonc/Nov213.23 |
0.349 |
|
| 2015 |
Amirian ES, Scheurer M, Armstrong G, Zhou R, Lau C, Claus E, Barnholtz-Sloan J, Il'yasova D, Schildkraut J, Ali-Osman F, Sadetzki S, Johansen C, Houlston R, Jenkins R, Lachance D, et al. EPID-01CHICKEN POX AND GLIOMA RISK: PRELIMINARY RESULTS FROM THE GLIOGENE INTERNATIONAL CASE-CONTROL STUDY Neuro-Oncology. 17: v78.1-v78. DOI: 10.1093/Neuonc/Nov213.01 |
0.309 |
|
| 2015 |
Jaeckle K, Vogelbaum M, Ballman K, Giannini C, Aldape K, Cerhan J, Wefel J, Nordstrom D, Jenkins R, Klein M, Raizer J, van den Bent M, Wick W, Flynn P, Dhermain F, et al. ATCT-16CODEL (ALLIANCE-N0577; EORTC-26081/2208; NRG-1071; NCIC-CEC-2): PHASE III RANDOMIZED STUDY OF RT VS. RT + TMZ VS. TMZ FOR NEWLY DIAGNOSED 1p/19q-CODELETED ANAPLASTIC GLIOMA. ANALYSIS OF PATIENTS TREATED ON THE ORIGINAL PROTOCOL DESIGN Neuro-Oncology. 17: v4.4-v5. DOI: 10.1093/Neuonc/Nov206.16 |
0.331 |
|
| 2015 |
Hu B, Fairey A, Madhav A, Yang D, Li M, Groshen S, Stephens C, Kim P, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins R, Den R, et al. MP37-19 AXIN2 EXPRESSION PREDICTS PROSTATE CANCER RECURRENCE AND MEDIATES AN INVASIVE, TUMORIGENIC PHENOTYPE Journal of Urology. 193. DOI: 10.1016/J.Juro.2015.02.1282 |
0.367 |
|
| 2014 |
Alshalalfa M, Crisan A, Vergara IA, Ghadessi M, Buerki C, Erho N, Yousefi K, Sierocinski T, Haddad Z, Black PC, Karnes RJ, Jenkins RB, Davicioni E. Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. Bju International. PMID 25762434 DOI: 10.1111/Bju.13013 |
0.331 |
|
| 2014 |
Prensner JR, Zhao S, Erho N, Schipper M, Iyer MK, Dhanasekaran SM, Magi-Galluzzi C, Mehra R, Sahu A, Siddiqui J, Davicioni E, Den RB, Dicker AP, Karnes RJ, Wei JT, ... ... Jenkins RB, et al. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. The Lancet. Oncology. 15: 1469-80. PMID 25456366 DOI: 10.1016/S1470-2045(14)71113-1 |
0.319 |
|
| 2014 |
Kizilbash SH, Giannini C, Voss JS, Decker PA, Jenkins RB, Hardie J, Laack NN, Parney IF, Uhm JH, Buckner JC. The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma. Journal of Neuro-Oncology. 120: 85-93. PMID 24993250 DOI: 10.1007/S11060-014-1520-4 |
0.346 |
|
| 2014 |
Walsh KM, Codd V, Smirnov IV, Rice T, Decker PA, Hansen HM, Kollmeyer T, Kosel ML, Molinaro AM, McCoy LS, Bracci PM, Cabriga BS, Pekmezci M, Zheng S, Wiemels JL, ... ... Jenkins RB, et al. Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nature Genetics. 46: 731-5. PMID 24908248 DOI: 10.1038/Ng.3004 |
0.328 |
|
| 2014 |
Jenkins RB. Editorial commentary on "Analysis of IDH mutation, 1p19q deletion, and PTEN loss delineates prognosis in clinical low-grade gliomas". Neuro-Oncology. 16: 891-2. PMID 24861880 DOI: 10.1093/Neuonc/Nou100 |
0.389 |
|
| 2014 |
Prensner JR, Sahu A, Iyer MK, Malik R, Chandler B, Asangani IA, Poliakov A, Vergara IA, Alshalalfa M, Jenkins RB, Davicioni E, Feng FY, Chinnaiyan AM. The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget. 5: 1434-8. PMID 24727738 DOI: 10.18632/Oncotarget.1846 |
0.312 |
|
| 2014 |
Andersson U, Wibom C, Cederquist K, Aradottir S, Borg A, Armstrong GN, Shete S, Lau CC, Bainbridge MN, Claus EB, Barnholtz-Sloan J, Lai R, Il'yasova D, Houlston RS, Schildkraut J, ... ... Jenkins RB, et al. Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer. Neuro-Oncology. 16: 1333-40. PMID 24723567 DOI: 10.1093/Neuonc/Nou052 |
0.317 |
|
| 2014 |
Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, Buckner JC, Fink KL, Souhami L, Laperriere NJ, Huse JT, Mehta MP, Curran WJ. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 783-90. PMID 24516018 DOI: 10.1200/Jco.2013.49.3726 |
0.383 |
|
| 2014 |
Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, Perkins SE, AlHilli M, Butler KA, McKinstry S, Fink S, Jenkins RB, Hou X, Kalli KR, Goodman KM, et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1288-97. PMID 24398046 DOI: 10.1158/1078-0432.Ccr-13-2611 |
0.367 |
|
| 2014 |
Yoon HH, Sukov WR, Shi Q, Sattler CA, Wiktor AE, Diasio RB, Wu TT, Jenkins RB, Sinicrope FA. HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma. Cancer. 120: 415-24. PMID 24151090 DOI: 10.1002/Cncr.28435 |
0.358 |
|
| 2014 |
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Archives of Pathology & Laboratory Medicine. 138: 241-56. PMID 24099077 DOI: 10.5858/Arpa.2013-0953-Sa |
0.32 |
|
| 2014 |
Trock BJ, Jenkins RB, Said JW, Fine S, Knudsen B, Fedor HL, Gurel B, Lotan TL, De Marzo AM. Chromosome 8 alterations and PTEN loss in Gleason grade 3 tumor to predict the presence of unsampled grade 4 tumor: Implications for active surveillance. Journal of Clinical Oncology. 32: 93-93. DOI: 10.1200/Jco.2014.32.4_Suppl.93 |
0.41 |
|
| 2014 |
Shah MV, Wiktor AE, Meyer RG, Tenner KS, Ballman KV, Ketterling RP, Perez EA, Jenkins RB. Changing pattern for HER2 positivity due to updated ASCO/CAP guidelines for HER2 testing and its impact. Journal of Clinical Oncology. 32: 523-523. DOI: 10.1200/Jco.2014.32.15_Suppl.523 |
0.321 |
|
| 2014 |
de Smith AJ, Walsh KM, Hansen HM, Barcellos LF, Chokkalingam AP, Jenkins RB, Wrensch MR, Wiencke JK, Metayer C, Wiemels JL. Missense SNP rs3731249 Explains the CDKN2A Association with Childhood ALL and Shows Risk Allele Selection in Tumors with Somatic CDKN2A Alterations Blood. 124: 129-129. DOI: 10.1182/Blood.V124.21.129.129 |
0.331 |
|
| 2014 |
Alshalalfa M, Vergara I, Erho N, Davicioni E, Jenkins R, Thomas K. Abstract 4720: Evaluation of a genomic classifier (Decipher®) in subsets of primary tumors with common prostate cancer genomic alterations Cancer Research. 74: 4720-4720. DOI: 10.1158/1538-7445.Am2014-4720 |
0.401 |
|
| 2014 |
Eckel-Passow JE, Kollmeyer TM, Sarkar G, Chada A, Decker PA, Kosel ML, Caron AA, Sicotte H, Nandakumar K, Prodduturi N, O'Neill BP, Lachance DH, Jenkins RB. Abstract 4714: The association of glioma germline risk SNPs with mutation-based molecular subgroups Cancer Research. 74: 4714-4714. DOI: 10.1158/1538-7445.Am2014-4714 |
0.334 |
|
| 2014 |
Eckel-Passow J, Lachance D, Walsh K, Decker P, Sicotte H, Pekmezci M, Molinaro A, Rice T, Kosel M, Smirnov I, Sarkar G, Caron A, Kollmeyer T, Giannini C, Huse J, ... ... Jenkins R, et al. GE-09 * TERT PROMOTER MUTATION, IDH MUTATION AND 1p/19q CODELETION DEFINE FIVE GLIOMA MOLECULAR GROUPS WITH SPECIFIC CLINICAL CHARACTERISTICS AND GERMLINE VARIANT ASSOCIATIONS Neuro-Oncology. 16: v98-v98. DOI: 10.1093/Neuonc/Nou256.9 |
0.351 |
|
| 2014 |
Walsh K, Codd V, Smirnov I, Rice T, Decker P, Hansen H, Molinaro A, Pekmezci M, Tihan T, Berger M, Chang S, Prados M, Lachance D, O'Neill BP, Harst Pvd, ... ... Jenkins R, et al. Ed-36Inherited Variants Near Terc And Tert Are Associated With Longer Telomeres And Increased Glioma Risk: Genome-Wide Association Results From The Ucsf Adult Glioma Study And The Engage Consortium Telomere Group Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou253.36 |
0.34 |
|
| 2014 |
Wrensch M, Walsh KM, Smirnov IV, Rice T, Hansen HM, Molinaro AM, McCoy LS, Bracci PM, Cabriga BS, Perry A, Marshall R, Pekmezci M, Zheng S, Wiemels JL, Tihan T, ... ... Jenkins R, et al. SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) ASSOCIATED WITH GLIOMA SURVIVAL Neuro-Oncology. 16: iii2-iii2. DOI: 10.1093/Neuonc/Nou206.7 |
0.365 |
|
| 2014 |
Walsh KM, Codd V, Smirnov IV, Rice T, Decker PA, Hansen HM, Kollmeyer T, Kosel ML, Molinaro AM, McCoy LS, Bracci PM, Cabriga BS, Pekmezci M, Zheng S, Wiemels JL, ... ... Jenkins RB, et al. Telomere Length Variants Are Associated With High-Grade Glioma Risk: Identification Of A Novel Glioma Risk Locus By Genome-Wide Association Study Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou206.4 |
0.358 |
|
| 2014 |
Jenkins RB, Decker P, Kosel M, Eckel-Passow J, Walsh KM, Smirnov IV, Caron A, Kollmeyer T, Rice T, Hansen HM, Molinaro AM, McCoy LS, Bracci PM, Cabriga BS, Marshall R, et al. MUTATION-BASED MOLECULAR GLIOMA CLASSIFICATION: PREVALENCE AND ASSOCIATION WITH GERMLINE RISK SNPS Neuro-Oncology. 16: iii1-iii1. DOI: 10.1093/Neuonc/Nou206.3 |
0.353 |
|
| 2014 |
Trock BJ, Jenkins RB, Said JW, Fine S, Knudsen B, Fedor HL, Gurel B, Lotan TL, De Marzo AM. MP79-09 CHROMOSOME 8 ALTERATIONS AND PTEN LOSS IN GLEASON GRADE 3 CORES PREDICT THE PRESENCE OF UNSAMPLED GRADE 4 TUMOR: IMPLICATIONS FOR ACTIVE SURVEILLANCE Journal of Urology. 191. DOI: 10.1016/J.Juro.2014.02.2512 |
0.377 |
|
| 2013 |
Bergstralh EJ, Erho N, Crisan A, Davicioni E, Buerki C, Mitra AP, Thompson DJ, Carlson R, Haddad Z, Zimmermann B, Ballman KV, Kollmeyer TM, Sierocinski T, Vergara IA, Triche TJ, ... ... Jenkins RB, et al. Validation of a genomic classifier that predicts metastatic disease progression in men with high-risk pathologic features postprostatectomy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 36. PMID 28136987 DOI: 10.1200/Jco.2013.31.6_Suppl.36 |
0.323 |
|
| 2013 |
Boardman LA, Johnson RA, Viker KB, Hafner KA, Jenkins RB, Riegert-Johnson DL, Smyrk TC, Litzelman K, Seo S, Gangnon RE, Engelman CD, Rider DN, Vanderboom RJ, Thibodeau SN, Petersen GM, et al. Correlation of chromosomal instability, telomere length and telomere maintenance in microsatellite stable rectal cancer: a molecular subclass of rectal cancer. Plos One. 8: e80015. PMID 24278232 DOI: 10.1371/Journal.Pone.0080015 |
0.389 |
|
| 2013 |
Melin B, Jenkins R. Genetics in glioma: Lessons learned from genome-wide association studies Current Opinion in Neurology. 26: 688-692. PMID 24184969 DOI: 10.1097/Wco.0000000000000033 |
0.388 |
|
| 2013 |
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3997-4013. PMID 24101045 DOI: 10.1200/Jco.2013.50.9984 |
0.318 |
|
| 2013 |
Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L, Vergara IA, Davicioni E, Erho N, Ghadessi M, Jenkins RB, Triche TJ, Malik R, Bedenis R, McGregor N, et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nature Genetics. 45: 1392-8. PMID 24076601 DOI: 10.1038/Ng.2771 |
0.323 |
|
| 2013 |
Dueck AC, Reinholz MM, Geiger XJ, Tenner K, Ballman K, Jenkins RB, Riehle D, Chen B, McCullough AE, Davidson NE, Martino S, Sledge GW, Kaufman PA, Kutteh LA, Gralow J, et al. Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 5798-807. PMID 23965903 DOI: 10.1158/1078-0432.Ccr-13-0558 |
0.387 |
|
| 2013 |
Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C, Bergstralh EJ, Kollmeyer T, Fink S, Haddad Z, Zimmermann B, Sierocinski T, Ballman KV, Triche TJ, Black PC, ... ... Jenkins RB, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. Plos One. 8: e66855. PMID 23826159 DOI: 10.1371/Journal.Pone.0066855 |
0.372 |
|
| 2013 |
Karnes RJ, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP, Crisan A, Erho N, Vergara IA, Lam LL, Carlson R, Thompson DJ, Haddad Z, Zimmermann B, Sierocinski T, ... ... Jenkins RB, et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. The Journal of Urology. 190: 2047-53. PMID 23770138 DOI: 10.1016/J.Juro.2013.06.017 |
0.35 |
|
| 2013 |
Walsh KM, Rice T, Decker PA, Kosel ML, Kollmeyer T, Hansen HM, Zheng S, McCoy LS, Bracci PM, Anderson E, Hsuang G, Wiemels JL, Pico AR, Smirnov I, Molinaro AM, ... ... Jenkins RB, et al. Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis. Neuro-Oncology. 15: 1041-7. PMID 23733245 DOI: 10.1093/Neuonc/Not051 |
0.343 |
|
| 2013 |
Perez EA, Dueck AC, McCullough AE, Chen B, Geiger XJ, Jenkins RB, Lingle WL, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris LN, Gralow JR, Reinholz MM. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 2115-22. PMID 23650412 DOI: 10.1200/Jco.2012.42.2642 |
0.4 |
|
| 2013 |
Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M, College of American Pathologists International Association for the Study of Lung Cancer and Association for Molecular Pathology. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. The Journal of Molecular Diagnostics : Jmd. 15: 415-53. PMID 23562183 DOI: 10.1016/J.Jmoldx.2013.03.001 |
0.307 |
|
| 2013 |
Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 823-59. PMID 23552377 DOI: 10.1097/Jto.0B013E318290868F |
0.307 |
|
| 2013 |
Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, Thunnissen E, Ladanyi M. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Archives of Pathology & Laboratory Medicine. 137: 828-60. PMID 23551194 DOI: 10.5858/Arpa.2012-0720-Oa |
0.307 |
|
| 2013 |
Perez EA, Press MF, Dueck AC, Jenkins RB, Kim C, Chen B, Villalobos I, Paik S, Buyse M, Wiktor AE, Meyer R, Finnigan M, Zujewski J, Shing M, Stern HM, et al. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Research and Treatment. 138: 99-108. PMID 23420271 DOI: 10.1007/S10549-013-2444-Y |
0.356 |
|
| 2013 |
Rice T, Zheng S, Decker PA, Walsh KM, Bracci P, Xiao Y, McCoy LS, Smirnov I, Patoka JS, Hansen HM, Hsuang G, Wiemels JL, Tihan T, Pico AR, Prados MD, ... ... Jenkins RB, et al. Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology. Neuro-Oncology. 15: 535-41. PMID 23361564 DOI: 10.1093/Neuonc/Nos324 |
0.373 |
|
| 2013 |
Mansfield AS, Sukov WR, Eckel-Passow JE, Sakai Y, Walsh FJ, Lonzo M, Wiktor AE, Dogan A, Jenkins RB. Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer. American Journal of Clinical Pathology. 139: 144-50. PMID 23355198 DOI: 10.1309/Ajcp13Gjaojayjmw |
0.341 |
|
| 2013 |
Drucker KL, Paulsen AR, Giannini C, Decker PA, Blaber SI, Blaber M, Uhm JH, O'Neill BP, Jenkins RB, Scarisbrick IA. Clinical significance and novel mechanism of action of kallikrein 6 in glioblastoma. Neuro-Oncology. 15: 305-18. PMID 23307575 DOI: 10.1093/Neuonc/Nos313 |
0.305 |
|
| 2013 |
Walsh KM, Anderson E, Hansen HM, Decker PA, Kosel ML, Kollmeyer T, Rice T, Zheng S, Xiao Y, Chang JS, McCoy LS, Bracci PM, Wiemels JL, Pico AR, Smirnov I, ... ... Jenkins RB, et al. Analysis of 60 reported glioma risk SNPs replicates published GWAS findings but fails to replicate associations from published candidate-gene studies. Genetic Epidemiology. 37: 222-8. PMID 23280628 DOI: 10.1002/Gepi.21707 |
0.316 |
|
| 2013 |
Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 337-43. PMID 23071247 DOI: 10.1200/Jco.2012.43.2674 |
0.35 |
|
| 2013 |
Yoon HH, Shi Q, Sukov WR, Sattler CA, Wiktor AE, Wu T, Diasio RB, Jenkins RB, Sinicrope FA. HER2 testing in esophageal adenocarcinoma (EAC) using parallel tissue-based methods. Journal of Clinical Oncology. 31: 2-2. DOI: 10.1200/Jco.2013.31.4_Suppl.2 |
0.345 |
|
| 2013 |
Sulman EP, Won M, Blumenthal DT, Vogelbaum MA, Colman H, Jenkins RB, Chakravarti A, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Dignam J, Atkins JN, Brachman D, Werner-Wasik M, et al. Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.Lba2010 |
0.345 |
|
| 2013 |
Yoon HH, Shi Q, Sukov WR, Sattler CA, Vaidya R, Wiktor AE, Diasio RB, Wu T, Jenkins RB, Sinicrope FA. HER2 status in primary tumors and metastatic regional lymph nodes in patients with esophageal adenocarcinoma (EAC). Journal of Clinical Oncology. 31: 4071-4071. DOI: 10.1200/Jco.2013.31.15_Suppl.4071 |
0.343 |
|
| 2013 |
Kizilbash SH, Giannini C, Voss JS, Decker PA, Jenkins RB, Laack NN, Parney IF, Uhm JH, Buckner JC. Impact of adjuvant temozolomide and IDH mutation status among patients with anaplastic astrocytoma. Journal of Clinical Oncology. 31: 2025-2025. DOI: 10.1200/Jco.2013.31.15_Suppl.2025 |
0.335 |
|
| 2013 |
Rynearson AL, Schowalter KA, Fink SR, Kollmeyer TM, Halder C, Sarkar G, Caron AA, Pauley RA, Lachance DH, O'Neill BP, Jenkins RB. Abstract 4207: The germline rs55705857 risk allele is not preferentially gained in gliomas with 8q24 duplication. Cancer Research. 73: 4207-4207. DOI: 10.1158/1538-7445.Am2013-4207 |
0.371 |
|
| 2012 |
Vergara IA, Buerki C, Ghadessi M, Crisan A, Sierocinski T, Haddad Z, Zimmermann B, Harko S, Sosu-Sedzorme W, Triche TJ, Jenkins RB, Davicioni E. Development and validation of a digital Gleason score biomarker signature for risk stratification of patients with prostate cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 40. PMID 28142490 DOI: 10.1200/Jco.2012.30.30_Suppl.40 |
0.323 |
|
| 2012 |
Ghadessi M, Buerki C, Vergara IA, Thompson DJ, Erho N, Sierocinski T, Haddad Z, Zimmermann B, Sosu-Sedzorme W, Harko S, Black PC, Davicioni E, Jenkins RB. Clinical and genomic analysis of metastatic disease progression in a background of biochemical recurrence. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 90. PMID 28142462 DOI: 10.1200/Jco.2012.30.30_Suppl.90 |
0.362 |
|
| 2012 |
Jenkins RB, Bergstralh EJ, Davicioni E, Karnes RJ, Ballman KV, Fink S, Black PC, Ghadessi M, Triche TJ, Klee GG, Kollmeyer TM, Vergara IA, Crisan A, Erho N, Sierocinski T, et al. Validation of a genomic-clinical classifier model for predicting clinical recurrence of patients with localized prostate cancer in a high-risk population. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 175. PMID 27968097 DOI: 10.1200/Jco.2012.30.5_Suppl.175 |
0.334 |
|
| 2012 |
Goodenberger ML, Jenkins RB. Genetics of adult glioma. Cancer Genetics. 205: 613-21. PMID 23238284 DOI: 10.1016/J.Cancergen.2012.10.009 |
0.379 |
|
| 2012 |
Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3932-8. PMID 22987085 DOI: 10.1200/Jco.2012.43.1890 |
0.409 |
|
| 2012 |
Hurley PJ, Marchionni L, Simons BW, Ross AE, Peskoe SB, Miller RM, Erho N, Vergara IA, Ghadessi M, Huang Z, Gurel B, Park BH, Davicioni E, Jenkins RB, Platz EA, et al. Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. Proceedings of the National Academy of Sciences of the United States of America. 109: 14977-82. PMID 22927397 DOI: 10.1073/Pnas.1203525109 |
0.315 |
|
| 2012 |
Jenkins RB, Xiao Y, Sicotte H, Decker PA, Kollmeyer TM, Hansen HM, Kosel ML, Zheng S, Walsh KM, Rice T, Bracci P, McCoy LS, Smirnov I, Patoka JS, Hsuang G, et al. A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nature Genetics. 44: 1122-5. PMID 22922872 DOI: 10.1038/Ng.2388 |
0.346 |
|
| 2012 |
Rajaraman P, Melin BS, Wang Z, McKean-Cowdin R, Michaud DS, Wang SS, Bondy M, Houlston R, Jenkins RB, Wrensch M, Yeager M, Ahlbom A, Albanes D, Andersson U, Freeman LE, et al. Genome-wide association study of glioma and meta-analysis. Human Genetics. 131: 1877-88. PMID 22886559 DOI: 10.1007/S00439-012-1212-0 |
0.405 |
|
| 2012 |
Cen L, Carlson BL, Schroeder MA, Ostrem JL, Kitange GJ, Mladek AC, Fink SR, Decker PA, Wu W, Kim JS, Waldman T, Jenkins RB, Sarkaria JN. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells. Neuro-Oncology. 14: 870-81. PMID 22711607 DOI: 10.1093/Neuonc/Nos114 |
0.312 |
|
| 2012 |
Liu Y, Melin BS, Rajaraman P, Wang Z, Linet M, Shete S, Amos CI, Lau CC, Scheurer ME, Tsavachidis S, Armstrong GN, Houlston RS, Hosking FJ, Claus EB, Barnholtz-Sloan J, ... ... Jenkins RB, et al. Insight in glioma susceptibility through an analysis of 6p22.3, 12p13.33-12.1, 17q22-23.2 and 18q23 SNP genotypes in familial and non-familial glioma. Human Genetics. 131: 1507-17. PMID 22688887 DOI: 10.1007/S00439-012-1187-X |
0.352 |
|
| 2012 |
Graham RP, Hodge JC, Folpe AL, Oliveira AM, Meyer KJ, Jenkins RB, Sim FH, Sukov WR. A cytogenetic analysis of 2 cases of phosphaturic mesenchymal tumor of mixed connective tissue type. Human Pathology. 43: 1334-8. PMID 22503486 DOI: 10.1016/J.Humpath.2011.11.020 |
0.373 |
|
| 2012 |
Itsara A, Vissers LE, Steinberg KM, Meyer KJ, Zody MC, Koolen DA, de Ligt J, Cuppen E, Baker C, Lee C, Graves TA, Wilson RK, Jenkins RB, Veltman JA, Eichler EE. Resolving the breakpoints of the 17q21.31 microdeletion syndrome with next-generation sequencing. American Journal of Human Genetics. 90: 599-613. PMID 22482802 DOI: 10.1016/J.Ajhg.2012.02.013 |
0.31 |
|
| 2012 |
Xiao Y, Decker PA, Rice T, McCoy LS, Smirnov I, Patoka JS, Hansen HM, Wiemels JL, Tihan T, Prados MD, Chang SM, Berger MS, Kosel ML, Fridley BL, Lachance DH, ... ... Jenkins RB, et al. SSBP2 variants are associated with survival in glioblastoma patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3154-62. PMID 22472174 DOI: 10.1158/1078-0432.Ccr-11-2778 |
0.37 |
|
| 2012 |
Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 546-54. PMID 22252257 DOI: 10.1158/1078-0432.Ccr-11-2272 |
0.38 |
|
| 2012 |
Perez EA, Dueck AC, McCullough AE, Reinholz MM, Tenner KS, Davidson NE, Gralow J, Harris LN, Kutteh LA, Hillman DW, Jenkins RB, Chen B. Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. Journal of the National Cancer Institute. 104: 159-62. PMID 22138096 DOI: 10.1093/Jnci/Djr490 |
0.344 |
|
| 2012 |
Singhi AD, Cimino-Mathews A, Jenkins RB, Lan F, Fink SR, Nassar H, Vang R, Fetting JH, Hicks J, Sukumar S, De Marzo AM, Argani P. MYC gene amplification is often acquired in lethal distant breast cancer metastases of unamplified primary tumors. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 25: 378-87. PMID 22056952 DOI: 10.1038/Modpathol.2011.171 |
0.375 |
|
| 2012 |
Bryce AH, Rao R, Sarkaria J, Reid JM, Qi Y, Qin R, James CD, Jenkins RB, Boni J, Erlichman C, Haluska P. Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors. Investigational New Drugs. 30: 1934-41. PMID 21881915 DOI: 10.1007/S10637-011-9742-1 |
0.321 |
|
| 2012 |
Mauermann M, Klein C, Dyck P, Engelstad J, Flynn Gilmer H, Jenkins R, Dyck PJB. FISH Analysis of Chromosome 22 from Peripheral Nerve Biopsies of Intraneural Perineurioma (P05.146) Neurology. 78: P05.146-P05.146. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P05.146 |
0.334 |
|
| 2012 |
Buerki C, Mitra AP, Black PC, Ghadessi M, Bergstralh EJ, Erho N, Carlson R, Crisan A, Sierocinski T, Zimmermann B, Haddad Z, Vergara IA, Ballman KV, Klee GG, Fink S, ... ... Jenkins RB, et al. Validation of a genomic-clinical classifier for predicting clinical progression in high-risk prostate cancer. Journal of Clinical Oncology. 30: 4565-4565. DOI: 10.1200/Jco.2012.30.15_Suppl.4565 |
0.347 |
|
| 2012 |
Yoon HH, Shi Q, Sukov WR, Sattler CA, Wiktor AE, Wu T, Diasio RB, Jenkins RB, Sinicrope FA. Adverse prognostic impact of heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma (EAC). Journal of Clinical Oncology. 30: 4009-4009. DOI: 10.1200/Jco.2012.30.15_Suppl.4009 |
0.422 |
|
| 2012 |
Cairncross JG, Wang M, Shaw EG, Jenkins RB, Scheithauer BW, Brachman D, Buckner JC, Fink KL, Souhami L, Laperriere N, Curran WJ, Mehta MP. Chemotherapy plus radiotherapy (CT-RT) versus RT alone for patients with anaplastic oligodendroglioma: Long-term results of the RTOG 9402 phase III study. Journal of Clinical Oncology. 30: 2008b-2008b. DOI: 10.1200/Jco.2012.30.15_Suppl.2008B |
0.368 |
|
| 2012 |
Crisan A, Davicioni E, Karnes RJ, Jenkins RB, Ghadessi MH, Buerki C, Bergstrahl EJ, Erho N, Vergara IA, Ballman KV, Black PC, Triche TJ. Abstract PR4: Biochemical recurrence is not a definitive surrogate endpoint for development of clinically useful predictive models for post-prostatectomy patients Cancer Research. 72: PR4-PR4. DOI: 10.1158/1538-7445.Prca2012-Pr4 |
0.352 |
|
| 2012 |
Erho N, Sierocinski T, Davicioni E, Jenkins RB, Gadhessi M, Buerki C, Vergara IA, Crisan A, Haddad Z, Zimmermann B, Mitra A, Triche TJ. Abstract B46: Identification of biomarkers for stratification of Gleason score 7 patients using whole-transcriptome expression profiling Cancer Research. 72: B46-B46. DOI: 10.1158/1538-7445.Prca2012-B46 |
0.37 |
|
| 2012 |
Perez E, Eckel-Passow J, Ballman K, Anderson S, Thompson E, Asmann Y, Jen J, Dueck A, Lingle W, Sledge G, Winer E, Gralow J, Jenkins R, Reinholz M. Abstract PD10-04: Predictive genomic markers to chemotherapy and adjuvant trastuzumab via whole genome expression DASL profiling in the N9831 adjuvant study Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-Pd10-04 |
0.366 |
|
| 2012 |
Ghadessi M, Bergstralh E, Buerki C, Black P, Erho N, Crisan A, Mitra A, Davicioni E, Feng F, Jenkins R. Validation of a Genomic-Clinical Classifier for Predicting Clinical Progression in Postprostatectomy High-risk Prostate Cancer International Journal of Radiation Oncology*Biology*Physics. 84: S58-S59. DOI: 10.1016/J.Ijrobp.2012.07.359 |
0.309 |
|
| 2011 |
Reinholz MM, Dueck AC, Chen B, Geiger X, McCullough AE, Jenkins RB, Lingle WL, Andorfer C, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris L, Gralow J, et al. Effect of IGF1R protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG N9831 trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10503. PMID 28022375 DOI: 10.1200/Jco.2011.29.15_Suppl.10503 |
0.309 |
|
| 2011 |
Perez EA, Dueck AC, Reinholz MM, Chen B, Geiger X, Jenkins RB, Lingle WL, Andorfer C, Davidson NE, Martino S, Kaufman PA, Kutteh LA, Sledge GW, Harris L, Gralow J, et al. Effect of PTEN protein expression on benefit to adjuvant trastuzumab in early-stage HER2+ breast cancer in NCCTG adjuvant trial N9831. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10504. PMID 28022372 DOI: 10.1200/Jco.2011.29.15_Suppl.10504 |
0.357 |
|
| 2011 |
Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu T, Diasio RB, Jenkins RB, Sinicrope F. HER2 expression/amplification: Frequency, clinicopathologic features, and prognosis in 713 patients with esophageal adenocarcinoma (EAC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4012. PMID 28020553 DOI: 10.1200/Jco.2011.29.15_Suppl.4012 |
0.308 |
|
| 2011 |
Brisbin AG, Asmann YW, Song H, Tsai YY, Aakre JA, Yang P, Jenkins RB, Pharoah P, Schumacher F, Conti DV, Duggan DJ, Jenkins M, Hopper J, Gallinger S, Newcomb P, et al. Meta-analysis of 8q24 for seven cancers reveals a locus between NOV and ENPP2 associated with cancer development. Bmc Medical Genetics. 12: 156. PMID 22142333 DOI: 10.1186/1471-2350-12-156 |
0.4 |
|
| 2011 |
Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, Chen B, Ingle JN, Dakhil SR, Zujewski J, Moreno-Aspitia A, Pisansky TM, Jenkins RB. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4491-7. PMID 22042958 DOI: 10.1200/Jco.2011.36.7045 |
0.316 |
|
| 2011 |
Shete S, Lau CC, Houlston RS, Claus EB, Barnholtz-Sloan J, Lai R, Il'yasova D, Schildkraut J, Sadetzki S, Johansen C, Bernstein JL, Olson SH, Jenkins RB, Yang P, Vick NA, et al. Genome-wide high-density SNP linkage search for glioma susceptibility loci: results from the Gliogene Consortium. Cancer Research. 71: 7568-75. PMID 22037877 DOI: 10.1158/0008-5472.Can-11-0013 |
0.359 |
|
| 2011 |
Stacey SN, Sulem P, Jonasdottir A, Masson G, Gudmundsson J, Gudbjartsson DF, Magnusson OT, Gudjonsson SA, Sigurgeirsson B, Thorisdottir K, Ragnarsson R, Benediktsdottir KR, Nexø BA, Tjønneland A, Overvad K, ... ... Jenkins RB, et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nature Genetics. 43: 1098-103. PMID 21946351 DOI: 10.1038/Ng.926 |
0.355 |
|
| 2011 |
Lachance DH, Yang P, Johnson DR, Decker PA, Kollmeyer TM, McCoy LS, Rice T, Xiao Y, Ali-Osman F, Wang F, Stoddard SM, Sprau DJ, Kosel ML, Wiencke JK, Wiemels JL, ... ... Jenkins RB, et al. Associations of high-grade glioma with glioma risk alleles and histories of allergy and smoking. American Journal of Epidemiology. 174: 574-81. PMID 21742680 DOI: 10.1093/Aje/Kwr124 |
0.336 |
|
| 2011 |
Jentoft M, Giannini C, Rossi S, Mota R, Jenkins RB, Rodriguez FJ. Oligodendroglial tumors with marked desmoplasia: clinicopathologic and molecular features of 7 cases. The American Journal of Surgical Pathology. 35: 845-52. PMID 21552114 DOI: 10.1097/Pas.0B013E3182189693 |
0.374 |
|
| 2011 |
Jenkins RB, Wrensch MR, Johnson D, Fridley BL, Decker PA, Xiao Y, Kollmeyer TM, Rynearson AL, Fink S, Rice T, McCoy LS, Halder C, Kosel ML, Giannini C, Tihan T, et al. Distinct germ line polymorphisms underlie glioma morphologic heterogeneity. Cancer Genetics. 204: 13-8. PMID 21356187 DOI: 10.1016/J.Cancergencyto.2010.10.002 |
0.368 |
|
| 2011 |
Perez EA, Jenkins RB, Dueck AC, Wiktor AE, Bedroske PP, Anderson SK, Ketterling RP, Sukov WR, Kanehira K, Chen B, Geiger XJ, Andorfer CA, McCullough AE, Davidson NE, Martino S, et al. C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 651-9. PMID 21245420 DOI: 10.1200/Jco.2010.30.2125 |
0.37 |
|
| 2011 |
Jaeckle KA, Decker PA, Ballman KV, Flynn PJ, Giannini C, Scheithauer BW, Jenkins RB, Buckner JC. Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis. Journal of Neuro-Oncology. 104: 253-9. PMID 21153680 DOI: 10.1007/S11060-010-0476-2 |
0.36 |
|
| 2011 |
Lasho TL, Tefferi A, Pardanani A, Finke C, Fink SR, Decker PA, Jenkins R. CCDC26 Polymorphisms Are Differentially Expressed in Myeloid Malignancies with Mutant IDH1 Compared to Their IDH2R140-Mutated or IDH-Unmutated Counterparts Blood. 118: 2807-2807. DOI: 10.1182/Blood.V118.21.2807.2807 |
0.309 |
|
| 2011 |
Cheng H, Rimm D, Reinholz M, Lingle W, Ballman K, Dueck A, Chen B, McCullough A, Jenkins R, Perez E. PD05-04: Quantitative Measurement of Antigen Degradation in NCCTG N9831 Tissue Microarrays. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Pd05-04 |
0.318 |
|
| 2011 |
Perez E, Ballman K, Reinholz M, Dueck A, Cheng H, Jenkins R, McCullough A, Chen B, Davidson N, Martino S, Kaufman P, Kutteh L, Sledge G, Geiger X, Ingle J, et al. PD05-03: Impact of Quantitative Measurement of HER2, HER3, HER4, EGFR, ER and PTEN Protein Expression on Benefit to Adjuvant Trastuzumab in Early-Stage HER2+ Breast Cancer Patients in NCCTG N9831. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Pd05-03 |
0.335 |
|
| 2011 |
Jenkins R, Crisan A, Erho N, Ballman K, Bergstralh E, Fink S, Kollmeyer T, Buerki C, Black P, Davicioni E. OP 29 Development of a genomic-clinical classifier model for predicting clinical recurrence in patients with localized prostate cancer European Journal of Cancer. 47: S8-S9. DOI: 10.1016/S0959-8049(11)72623-5 |
0.316 |
|
| 2010 |
Reinholz MM, Eckel-Passow JE, Anderson SK, Asmann YW, Zschunke MA, Oberg AL, McCullough AE, Dueck AC, Chen B, April CS, Wickham-Garcia E, Jenkins RB, Cunningham JM, Jen J, Perez EA, et al. Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platform. Bmc Medical Genomics. 3: 60. PMID 21172013 DOI: 10.1186/1755-8794-3-60 |
0.33 |
|
| 2010 |
D'Assoro AB, Leontovich A, Amato A, Ayers-Ringler JR, Quatraro C, Hafner K, Jenkins RB, Libra M, Ingle J, Stivala F, Galanis E, Salisbury JL. Abrogation of p53 function leads to metastatic transcriptome networks that typify tumor progression in human breast cancer xenografts. International Journal of Oncology. 37: 1167-76. PMID 20878064 DOI: 10.3892/Ijo_00000768 |
0.381 |
|
| 2010 |
Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, Martino S, Sledge GW, Harris LN, Gralow JR, Dueck AC, Ketterling RP, Ingle JN, Lingle WL, Kaufman PA, ... ... Jenkins RB, et al. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4307-15. PMID 20697084 DOI: 10.1200/Jco.2009.26.2154 |
0.408 |
|
| 2010 |
Huang W, Reinholz M, Weidler J, Yolanda L, Paquet A, Whitcomb J, Lingle W, Jenkins RB, Chen B, Larson JS, Tan Y, Sherwood T, Bates M, Perez EA. Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay. American Journal of Clinical Pathology. 134: 303-11. PMID 20660336 DOI: 10.1309/Ajcp3Bzy4Yafntrg |
0.305 |
|
| 2010 |
Gray-McGuire C, Guda K, Adrianto I, Lin CP, Natale L, Potter JD, Newcomb P, Poole EM, Ulrich CM, Lindor N, Goode EL, Fridley BL, Jenkins R, Le Marchand L, Casey G, et al. Confirmation of linkage to and localization of familial colon cancer risk haplotype on chromosome 9q22. Cancer Research. 70: 5409-18. PMID 20551049 DOI: 10.1158/0008-5472.Can-10-0188 |
0.37 |
|
| 2010 |
Swartling FJ, Grimmer MR, Hackett CS, Northcott PA, Fan QW, Goldenberg DD, Lau J, Masic S, Nguyen K, Yakovenko S, Zhe XN, Gilmer HC, Collins R, Nagaoka M, Phillips JJ, ... Jenkins RB, et al. Pleiotropic role for MYCN in medulloblastoma. Genes & Development. 24: 1059-72. PMID 20478998 DOI: 10.1101/Gad.1907510 |
0.354 |
|
| 2010 |
Robertson LB, Armstrong GN, Olver BD, Lloyd AL, Shete S, Lau C, Claus EB, Barnholtz-Sloan J, Lai R, Il'yasova D, Schildkraut J, Bernstein JL, Olson SH, Jenkins RB, Yang P, et al. Survey of familial glioma and role of germline p16INK4A/p14ARF and p53 mutation. Familial Cancer. 9: 413-21. PMID 20455025 DOI: 10.1007/S10689-010-9346-5 |
0.309 |
|
| 2010 |
Bender AM, Collier LS, Rodriguez FJ, Tieu C, Larson JD, Halder C, Mahlum E, Kollmeyer TM, Akagi K, Sarkar G, Largaespada DA, Jenkins RB. Sleeping beauty-mediated somatic mutagenesis implicates CSF1 in the formation of high-grade astrocytomas. Cancer Research. 70: 3557-65. PMID 20388773 DOI: 10.1158/0008-5472.Can-09-4674 |
0.343 |
|
| 2010 |
Kelly JJ, Blough MD, Stechishin OD, Chan JA, Beauchamp D, Perizzolo M, Demetrick DJ, Steele L, Auer RN, Hader WJ, Westgate M, Parney IF, Jenkins R, Cairncross JG, Weiss S. Oligodendroglioma cell lines containing t(1;19)(q10;p10). Neuro-Oncology. 12: 745-55. PMID 20388696 DOI: 10.1093/Neuonc/Noq031 |
0.358 |
|
| 2010 |
Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, Popoff S, Nutt CL, Louis DN, Cairncross JG, Gilbert MR, Phillips HS, Mehta MP, Chakravarti A, Pelloski CE, ... ... Jenkins RB, et al. A multigene predictor of outcome in glioblastoma. Neuro-Oncology. 12: 49-57. PMID 20150367 DOI: 10.1093/Neuonc/Nop007 |
0.326 |
|
| 2010 |
Wang X, Zamolyi RQ, Zhang H, Pannain VL, Medeiros F, Erickson-Johnson M, Jenkins RB, Oliveira AM. Fusion of HMGA1 to the LPP/TPRG1 intergenic region in a lipoma identified by mapping paraffin-embedded tissues. Cancer Genetics and Cytogenetics. 196: 64-7. PMID 19963137 DOI: 10.1016/J.Cancergencyto.2009.09.003 |
0.312 |
|
| 2010 |
Perez E, Dueck A, Press M, Chen B, Jenkins R, Paik S, Kim C, Wiktor A, Meyer R, Ketterling R, Villalobos I, Finnigan M, Buyse M, Zujewski J, Shing M, et al. Abstract PD10-02: Round-Robin Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer (NCCTG N9831/BCIRG006/BCIRG005) Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-Pd10-02 |
0.338 |
|
| 2010 |
McCullough A, Dell'Orto P, Reinholz M, Gelber R, Dueck A, Russo L, Jenkins R, Andrighetto S, Chen B, Lingle W, Jackisch C, Perez E, Piccart-Gebhart M, Viale G. Abstract P3-10-36: Concordance of HER2 Central Assessment by Two International Central Laboratories: A Ring Study within the Framework of the Adjuvant HER2-Positive ALTTO Trial (BIG2-06/N063D/EGF106708) Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P3-10-36 |
0.317 |
|
| 2010 |
Reinholz M, Dueck A, Wiktor A, Lingle W, Jenkins R, Davidson N, Martino S, Kaufman P, Kutteh L, Sledge G, Harris L, Gralow J, Geiger X, Perez E. Abstract P2-09-08: c-MYC (MYC) Protein Expression and Associations with Trastuzumab Benefit in Early-Stage, HER2+ Breast Cancer in Context of the NCCTG Adjuvant Trial, N9831 Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P2-09-08 |
0.365 |
|
| 2009 |
McCullough A, Dueck A, Chen B, Reinholz M, Wiktor A, Lingle W, Jenkins R, Perez E. HER-2 central confirmatory testing using ASCO/CAP guidelines for trastuzumab/lapatinib trial MCCR RC0639. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e11527. PMID 27964626 DOI: 10.1200/Jco.2009.27.15_Suppl.E11527 |
0.306 |
|
| 2009 |
Sukov WR, Miller DV, Dueck AC, Tenner KS, Jenkins RB, Kaufman PA, Davidson NE, Dakhil SR, Martino S, Roy V, Perez EA. Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: Data from N9831 Intergroup Adjuvant Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 520. PMID 27960675 DOI: 10.1200/Jco.2009.27.15_Suppl.520 |
0.338 |
|
| 2009 |
Collier LS, Adams DJ, Hackett CS, Bendzick LE, Akagi K, Davies MN, Diers MD, Rodriguez FJ, Bender AM, Tieu C, Matise I, Dupuy AJ, Copeland NG, Jenkins NA, Hodgson JG, ... ... Jenkins RB, et al. Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality. Cancer Research. 69: 8429-37. PMID 19843846 DOI: 10.1158/0008-5472.Can-09-1760 |
0.353 |
|
| 2009 |
Steensma DP, Neiger JD, Porcher JC, Keats JJ, Bergsagel PL, Dennis TR, Knudson RA, Jenkins RB, Santana-Davila R, Kumar R, Ketterling RP. Rearrangements and amplification of IER3 (IEX-1) represent a novel and recurrent molecular abnormality in myelodysplastic syndromes. Cancer Research. 69: 7518-23. PMID 19773435 DOI: 10.1158/0008-5472.Can-09-1428 |
0.368 |
|
| 2009 |
Rossi S, Rodriguez F, Dei Tos A, Di Paola F, Bendini M, Jenkins R, Giannini C. Re: Diffuse leptomeningeal glioneuronal tumors: a new entity? Brain Pathology (Zurich, Switzerland). 19: 745; author reply 74. PMID 19744049 DOI: 10.1111/J.1750-3639.2009.00330.X |
0.323 |
|
| 2009 |
Cicek MS, Slager SL, Achenbach SJ, French AJ, Blair HE, Fink SR, Foster NR, Kabat BF, Halling KC, Cunningham JM, Cerhan JR, Jenkins RB, Boardman LA, Petersen GM, Sargent DJ, et al. Functional and clinical significance of variants localized to 8q24 in colon cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 18: 2492-500. PMID 19690179 DOI: 10.1158/1055-9965.Epi-09-0362 |
0.408 |
|
| 2009 |
Wrensch M, Jenkins RB, Chang JS, Yeh RF, Xiao Y, Decker PA, Ballman KV, Berger M, Buckner JC, Chang S, Giannini C, Halder C, Kollmeyer TM, Kosel ML, LaChance DH, et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nature Genetics. 41: 905-8. PMID 19578366 DOI: 10.1038/Ng.408 |
0.345 |
|
| 2009 |
Rossi S, Rodriguez FJ, Mota RA, Dei Tos AP, Di Paola F, Bendini M, Agostini S, Longatti P, Jenkins RB, Giannini C. Primary leptomeningeal oligodendroglioma with documented progression to anaplasia and t(1;19)(q10;p10) in a child. Acta Neuropathologica. 118: 575-7. PMID 19562354 DOI: 10.1007/S00401-009-0565-5 |
0.364 |
|
| 2009 |
Drucker KL, Kitange GJ, Kollmeyer TM, Law ME, Passe S, Rynearson AL, Blair H, Soderberg CL, Morlan BW, Ballman KV, Giannini C, Jenkins RB. Characterization and gene expression profiling in glioma cell lines with deletion of chromosome 19 before and after microcell-mediated restoration of normal human chromosome 19. Genes, Chromosomes & Cancer. 48: 854-64. PMID 19544381 DOI: 10.1002/Gcc.20688 |
0.39 |
|
| 2009 |
Wang X, Hulshizer RL, Erickson-Johnson MR, Flynn HC, Jenkins RB, Lloyd RV, Oliveira AM. Identification of novel HMGA2 fusion sequences in lipoma: evidence that deletion of let-7 miRNA consensus binding site 1 in the HMGA2 3' UTR is not critical for HMGA2 transcriptional upregulation. Genes, Chromosomes & Cancer. 48: 673-8. PMID 19431195 DOI: 10.1002/Gcc.20674 |
0.326 |
|
| 2009 |
Vance GH, Barry TS, Bloom KJ, Fitzgibbons PL, Hicks DG, Jenkins RB, Persons DL, Tubbs RR, Hammond ME. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Archives of Pathology & Laboratory Medicine. 133: 611-2. PMID 19391661 DOI: 10.1043/1543-2165-133.4.611 |
0.337 |
|
| 2009 |
Reinholz MM, Bruzek AK, Visscher DW, Lingle WL, Schroeder MJ, Perez EA, Jenkins RB. Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. The Lancet. Oncology. 10: 267-77. PMID 19261255 DOI: 10.1016/S1470-2045(09)70063-4 |
0.37 |
|
| 2009 |
Rodriguez FJ, Scheithauer BW, Erickson LA, Jenkins RB, Giannini C. Ectopic low-grade adrenocortical carcinoma in the spinal region: immunohistochemical and molecular cytogenetic study of a pediatric case. The American Journal of Surgical Pathology. 33: 142-8. PMID 18941403 DOI: 10.1097/Pas.0B013E318180Deda |
0.347 |
|
| 2009 |
Vogelbaum MA, Berkey B, Peereboom D, Macdonald D, Giannini C, Suh JH, Jenkins R, Herman J, Brown P, Blumenthal DT, Biggs C, Schultz C, Mehta M. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131. Neuro-Oncology. 11: 167-75. PMID 18779504 DOI: 10.1215/15228517-2008-073 |
0.363 |
|
| 2009 |
Rodriguez FJ, Mota RA, Scheithauer BW, Giannini C, Blair H, New KC, Wu KJ, Dickson DW, Jenkins RB. Interphase cytogenetics for 1p19q and t(1;19)(q10;p10) may distinguish prognostically relevant subgroups in extraventricular neurocytoma. Brain Pathology (Zurich, Switzerland). 19: 623-9. PMID 18710393 DOI: 10.1111/J.1750-3639.2008.00206.X |
0.38 |
|
| 2009 |
Cen L, Ostrem JL, Schroeder MA, Mladek AC, Fink SR, Jenkins RB, Sarkaria JN. Abstract C191: The effect of the cyclin‐dependent kinase inhibitor PD 0332991 on glioblastoma cells and relationship with p15INK4B/p16INK4A expression Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C191 |
0.311 |
|
| 2009 |
Perez E, Reinholz M, Dueck A, Wiktor A, Lingle W, Davidson N, Martino S, Kaufman P, Kutteh L, Jenkins R. c-MYC amplification and correlation with patient outcome in early stage HER2+ breast cancer from the NCCTG adjuvant intergroup trial N9831. Cancer Research. 69: 56. DOI: 10.1158/0008-5472.Sabcs-56 |
0.334 |
|
| 2009 |
Perez E, Suman V, Davidson N, Gralow J, Kaufman P, Ingle J, Dakhil S, Zujewski J, Pisansky T, Jenkins R. Results of Chemotherapy Alone, with Sequential or Concurrent Addition of 52 Weeks of Trastuzumab in the NCCTG N9831 HER2-Positive Adjuvant Breast Cancer Trial. Cancer Research. 69: 80-80. DOI: 10.1158/0008-5472.Sabcs-09-80 |
0.313 |
|
| 2009 |
Perez E, Reinholz M, Dueck A, Tenner K, Davidson N, Gralow J, Harris L, Kutteh L, Jenkins R, Chen B. Do the ASCO/CAP 2007 HER2 Testing Guidelines Improve Prediction of Benefit to Adjuvant Trastuzumab?: Data from North Central Cancer Treatment Group N9831 Adjuvant Trial. Cancer Research. 69: 701-701. DOI: 10.1158/0008-5472.Sabcs-09-701 |
0.358 |
|
| 2008 |
Reinholz MM, Dueck AC, Lingle WL, Allen Ziegler KL, Wiktor AE, Paik S, Jenkins RB, Perez EA. The concordance between NCCTG's and NSABP's C-myc FISH assays. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 22110. PMID 27950689 DOI: 10.1200/Jco.2008.26.15_Suppl.22110 |
0.336 |
|
| 2008 |
Cairncross G, Jenkins R. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer Journal. 14: 352-357. PMID 19060598 DOI: 10.1097/Ppo.0B013E31818D8178 |
0.392 |
|
| 2008 |
Rodriguez FJ, Giannini C, Asmann YW, Sharma MK, Perry A, Tibbetts KM, Jenkins RB, Scheithauer BW, Anant S, Jenkins S, Eberhart CG, Sarkaria JN, Gutmann DH. Gene expression profiling of NF-1-associated and sporadic pilocytic astrocytoma identifies aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed candidate biomarker in aggressive subtypes. Journal of Neuropathology and Experimental Neurology. 67: 1194-204. PMID 19018242 DOI: 10.1097/Nen.0B013E31818Fbe1E |
0.311 |
|
| 2008 |
Brown PD, Krishnan S, Sarkaria JN, Wu W, Jaeckle KA, Uhm JH, Geoffroy FJ, Arusell R, Kitange G, Jenkins RB, Kugler JW, Morton RF, Rowland KM, Mischel P, Yong WH, et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 5603-9. PMID 18955445 DOI: 10.1200/Jco.2008.18.0612 |
0.33 |
|
| 2008 |
Nakagawa T, Kollmeyer TM, Morlan BW, Anderson SK, Bergstralh EJ, Davis BJ, Asmann YW, Klee GG, Ballman KV, Jenkins RB. A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. Plos One. 3: e2318. PMID 18846227 DOI: 10.1371/Journal.Pone.0002318 |
0.345 |
|
| 2008 |
Rodriguez FJ, Scheithauer BW, Giannini C, Bryant SC, Jenkins RB. Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study. Cancer. 113: 2779-89. PMID 18816605 DOI: 10.1002/Cncr.23899 |
0.416 |
|
| 2008 |
Gurel B, Iwata T, Koh CM, Jenkins RB, Lan F, Van Dang C, Hicks JL, Morgan J, Cornish TC, Sutcliffe S, Isaacs WB, Luo J, De Marzo AM. Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 21: 1156-67. PMID 18567993 DOI: 10.1038/Modpathol.2008.111 |
0.323 |
|
| 2008 |
Gilbert JA, Goetz MP, Reynolds CA, Ingle JN, Giordano KF, Suman VJ, Blair HE, Jenkins RB, Lingle WL, Reinholz MM, Adjei AA, Ames MM. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Molecular Cancer Therapeutics. 7: 944-51. PMID 18413808 DOI: 10.1158/1535-7163.Mct-07-0570 |
0.316 |
|
| 2008 |
Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, Curran WJ, Aldape K. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathology (Zurich, Switzerland). 18: 360-9. PMID 18371182 DOI: 10.1111/J.1750-3639.2008.00129.X |
0.402 |
|
| 2008 |
Rodriguez FJ, Scheithauer BW, Perry A, Oliveira AM, Jenkins RB, Oviedo A, Mork SJ, Palmer CA, Burger PC. Ependymal tumors with sarcomatous change ("ependymosarcoma"): a clinicopathologic and molecular cytogenetic study. The American Journal of Surgical Pathology. 32: 699-709. PMID 18347506 DOI: 10.1097/Pas.0B013E318158234E |
0.322 |
|
| 2008 |
Rodriguez FJ, Thibodeau SN, Jenkins RB, Schowalter KV, Caron BL, O'neill BP, James CD, David James C, Passe S, Slezak J, Giannini C. MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Applied Immunohistochemistry & Molecular Morphology : Aimm / Official Publication of the Society For Applied Immunohistochemistry. 16: 59-65. PMID 18091318 DOI: 10.1097/Pai.0B013E31802Fac2F |
0.306 |
|
| 2007 |
Zhang H, MacDonald WD, Erickson-Johnson M, Wang X, Jenkins RB, Oliveira AM. Cytogenetic and molecular cytogenetic findings of intimal sarcoma Cancer Genetics and Cytogenetics. 179: 146-149. PMID 18036403 DOI: 10.1016/J.Cancergencyto.2007.08.013 |
0.388 |
|
| 2007 |
Ida CM, Rolig KA, Hulshizer RL, Van Dyke DL, Randolph JL, Jenkins RB, Nascimento AG, Oliveira AM. Myxoinflammatory fibroblastic sarcoma showing t(2;6)(q31;p21.3) as a sole cytogenetic abnormality Cancer Genetics and Cytogenetics. 177: 139-142. PMID 17854670 DOI: 10.1016/J.Cancergencyto.2007.05.018 |
0.357 |
|
| 2007 |
Rodriguez FJ, Scheithauer BW, Jenkins R, Burger PC, Rudzinskiy P, Vlodavsky E, Schooley A, Landolfi J. Gliosarcoma arising in oligodendroglial tumors ("oligosarcoma"): a clinicopathologic study. The American Journal of Surgical Pathology. 31: 351-62. PMID 17325476 DOI: 10.1097/01.Pas.0000213378.94547.Ae |
0.322 |
|
| 2007 |
Vencio EF, Jenkins RB, Schiller JL, Huynh TVT, Wenger DD, Inwards CY, Oliveira AM. Clonal cytogenetic abnormalities in Erdheim-Chester disease American Journal of Surgical Pathology. 31: 319-321. PMID 17255779 DOI: 10.1097/01.Pas.0000213366.33627.A0 |
0.349 |
|
| 2007 |
Macarenco RS, Erickson-Johnson M, Wang X, Jenkins RB, Nascimento AG, Oliveira AM. Cytogenetic and molecular cytogenetic findings in dedifferentiated liposarcoma with neural-like whorling pattern and metaplastic bone formation Cancer Genetics and Cytogenetics. 172: 147-150. PMID 17213023 DOI: 10.1016/J.Cancergencyto.2006.07.019 |
0.353 |
|
| 2007 |
Leenstra JL, Rodriguez FJ, Frechette CM, Giannini C, Stafford SL, Pollock BE, Schild SE, Scheithauer BW, Jenkins RB, Buckner JC, Brown PD. Central neurocytoma: management recommendations based on a 35-year experience. International Journal of Radiation Oncology, Biology, Physics. 67: 1145-54. PMID 17187939 DOI: 10.1016/J.Ijrobp.2006.10.018 |
0.35 |
|
| 2007 |
Jenkins RB, Nakagawa T, Kollmeyer T, Morlan B, Bergstrahl E, Davis B, Klee G, Ballman KV. Use of a tissue biomarker panel to predict which men with a rising PSA post-definitive prostate cancer therapy will have systemic progression Journal of Clinical Oncology. 25: 5017-5017. DOI: 10.1200/Jco.2007.25.18_Suppl.5017 |
0.342 |
|
| 2007 |
Komori T, Silva AI, Scheithauer BW, Hirose T, Jenkins R. An immunocytologic and ultrastructural study of oligodendroglial tumors with respect to chromosome 1p deletion Journal of Neuropathology and Experimental Neurology. 66: 443-444. DOI: 10.1097/01.Jnen.0000268913.11892.0A |
0.381 |
|
| 2007 |
Komori T, Silva AI, Scheithauer BW, Hirose T, Jenkins R. An immunocytologic and ultrastructural study of oligodendroglial tumors with respect to chromosome 1p deletion The Faseb Journal. 21. DOI: 10.1096/Fasebj.21.5.A393-B |
0.381 |
|
| 2006 |
Bethel CR, Faith D, Li X, Guan B, Hicks JL, Lan F, Jenkins RB, Bieberich CJ, De Marzo AM. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. Cancer Research. 66: 10683-90. PMID 17108105 DOI: 10.1158/0008-5472.Can-06-0963 |
0.35 |
|
| 2006 |
Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma Cancer Research. 66: 9852-9861. PMID 17047046 DOI: 10.1158/0008-5472.Can-06-1796 |
0.388 |
|
| 2006 |
Shanafelt TD, Witzig TE, Fink SR, Jenkins RB, Paternoster SF, Smoley SA, Stockero KJ, Nast DM, Flynn HC, Tschumper RC, Geyer S, Zent CS, Call TG, Jelinek DF, Kay NE, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4634-41. PMID 17008705 DOI: 10.1200/Jco.2006.06.9492 |
0.347 |
|
| 2006 |
Oblinger JL, Pearl DK, Boardman CL, Saqr H, Prior TW, Scheithauer BW, Jenkins RB, Burger PC, Yates AJ. Diagnostic and prognostic value of glycosyltransferase mRNA in glioblastoma multiforme patients. Neuropathology and Applied Neurobiology. 32: 410-8. PMID 16866986 DOI: 10.1111/J.1365-2990.2006.00742.X |
0.335 |
|
| 2006 |
Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB. HER2 testing by local, central, and reference laboratories in specimens from the north central cancer treatment group N9831 intergroup adjuvant trial Journal of Clinical Oncology. 24: 3032-3038. PMID 16809727 DOI: 10.1200/Jco.2005.03.4744 |
0.34 |
|
| 2006 |
Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta M, Curran W. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 2707-14. PMID 16782910 DOI: 10.1200/Jco.2005.04.3414 |
0.323 |
|
| 2006 |
Murillo H, Schmidt LJ, Karter M, Hafner KA, Kondo Y, Ballman KV, Vasmatzis G, Jenkins RB, Tindall DJ. Prostate cancer cells use genetic and epigenetic mechanisms for progression to androgen independence. Genes, Chromosomes & Cancer. 45: 702-16. PMID 16615098 DOI: 10.1002/Gcc.20333 |
0.363 |
|
| 2006 |
Jaeckle KA, Ballman KV, Rao RD, Jenkins RB, Buckner JC. Current strategies in treatment of oligodendroglioma: Evolution of molecular signatures of response Journal of Clinical Oncology. 24: 1246-1252. PMID 16525179 DOI: 10.1200/Jco.2005.04.9874 |
0.416 |
|
| 2006 |
Jaeckle KA, Decker PA, Ballman KV, Flynn PJ, Giannini C, Scheithauer BW, Jenkins RB, Buckner JC. Analysis of paired glioma tissues from initial diagnosis and recurrence in patients enrolled on NCCTG clinical trials: De-differentiation and association with survival Journal of Clinical Oncology. 24: 1521-1521. DOI: 10.1200/Jco.2006.24.18_Suppl.1521 |
0.337 |
|
| 2006 |
Vogelbaum MA, Berkey B, Peereboom D, Giannini C, Jenkins R, Suh J, Brown P, Blumenthal D, Biggs C, Mehta M. RTOG 0131: Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas: Relationship between 1p/19q status and progression-free survival Journal of Clinical Oncology. 24: 1517-1517. DOI: 10.1200/Jco.2006.24.18_Suppl.1517 |
0.423 |
|
| 2006 |
Jenkins RB, Ballman KV, Giannini C, Arusell RM, Blair H, Passe S, Flynn H, Brown P, Shaw EG, Buckner JC. Diagnostic and prognostic significance of a t(1;19)(q10;p10) in patients (pts) with low-grade oligodendroglioma and astrocytoma: NCCTG 94–72–53 Journal of Clinical Oncology. 24: 1505-1505. DOI: 10.1200/Jco.2006.24.18_Suppl.1505 |
0.393 |
|
| 2005 |
Buckner JC, Ballman KV, Scheithauer BW, Arusell RM, Blair HE, Passe SM, Brown PD, Jaeckle KA, Shaw EG, Jenkins RB. NCCTG 94-72-53: Diagnostic and prognostic significance of 1p and 19q deletions in patients (pts) with low-grade oligodendroglioma and astrocytoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 1502. PMID 27947096 DOI: 10.1200/Jco.2005.23.16_Suppl.1502 |
0.4 |
|
| 2005 |
McDonald JM, See SJ, Tremont IW, Colman H, Gilbert MR, Groves M, Burger PC, Louis DN, Giannini C, Fuller G, Passe S, Blair H, Jenkins RB, Yang H, Ledoux A, et al. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer. 104: 1468-77. PMID 16088966 DOI: 10.1002/Cncr.21338 |
0.305 |
|
| 2005 |
Lewis JT, Ketterling RP, Halling KC, Reynolds C, Jenkins RB, Visscher DW. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining American Journal of Clinical Pathology. 124: 273-281. PMID 16040300 DOI: 10.1309/J9Vxabugkc4Y07Dl |
0.33 |
|
| 2005 |
Mistry SH, Taylor C, Randerson-Moor JA, Harland M, Turner F, Barrett JH, Whitaker L, Jenkins RB, Knowles MA, Bishop JAN, Bishop DT. Prevalence of 9p21 deletions in UK melanoma families Genes Chromosomes and Cancer. 44: 292-300. PMID 16032697 DOI: 10.1002/Gcc.20238 |
0.348 |
|
| 2005 |
Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5294-304. PMID 15998902 DOI: 10.1200/Jco.2005.23.622 |
0.352 |
|
| 2005 |
Law ME, Templeton KL, Kitange G, Smith J, Misra A, Feuerstein BG, Jenkins RB. Molecular cytogenetic analysis of chromosomes 1 and 19 in glioma cell lines. Cancer Genetics and Cytogenetics. 160: 1-14. PMID 15949564 DOI: 10.1016/J.Cancergencyto.2004.11.012 |
0.362 |
|
| 2005 |
Pelloski CE, Mahajan A, Maor M, Chang EL, Woo S, Gilbert M, Colman H, Yang H, Ledoux A, Blair H, Passe S, Jenkins RB, Aldape KD. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 3326-34. PMID 15867231 DOI: 10.1158/1078-0432.Ccr-04-1765 |
0.357 |
|
| 2005 |
Palacios J, Honrado E, Cigudosa JC, Benítez J, Jenkins RB, Adem C, Couch FJ, Hartmann LC. ERBB2 and MYC alterations in BRCAI- and BRCA2-associated cancers [2] (multiple letters) Genes, Chromosomes and Cancer. 42: 204-206. PMID 15543618 DOI: 10.1002/Gcc.20125 |
0.3 |
|
| 2005 |
Kitange G, Misra A, Law M, Passe S, Kollmeyer TM, Maurer M, Ballman K, Feuerstein BG, Jenkins RB. Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas Genes Chromosomes and Cancer. 42: 68-77. PMID 15472895 DOI: 10.1002/Gcc.20108 |
0.379 |
|
| 2005 |
Galanis E, Buckner JC, Maurer MJ, Hidalgo M, Kreisberg JI, Peralba J, Jenkins RB, Walsh DJ. N997B: Phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM): Updated results and correlative laboratory analysis Journal of Clinical Oncology. 23: 1505-1505. DOI: 10.1200/Jco.2005.23.16_Suppl.1505 |
0.303 |
|
| 2005 |
Shanafelt TD, Fink S, Witzig TE, Paternoster SF, Smoley S, Stockero K, Flynn HC, Almer C, Jenkins R, Geyer S, Kay NE, Dewald G. Frequency of Clonal Evolution by FISH in Untreated, Early Stage Patients with CLL: A Prospective, Longitudinal Study with Long Clinical Follow-Up. Blood. 106: 2098-2098. DOI: 10.1182/Blood.V106.11.2098.2098 |
0.366 |
|
| 2004 |
Perez EA, Suman VJ, Davidson NE, Martino S, Kaufman PA, Lingle WL, Flynn PJ, Ingle JN, Visscher D, Jenkins RB. HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 567. PMID 28016470 DOI: 10.1200/Jco.2004.22.14_Suppl.567 |
0.311 |
|
| 2004 |
Miller DV, Jenkins RB, Lingle WL, Davidson NE, Kaufman PA, Martino S, Dakhil SR, Perez EA. Focal HER2/neu amplified clones partially account for discordance between immunohistochemistry and fluorescence in-situ hybridization results: data from NCCTG N9831 Intergroup Adjuvant Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 568. PMID 28016459 DOI: 10.1200/Jco.2004.22.14_Suppl.568 |
0.353 |
|
| 2004 |
Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, James CD. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. Journal of Neuropathology and Experimental Neurology. 63: 700-7. PMID 15290895 DOI: 10.1093/Jnen/63.7.700 |
0.396 |
|
| 2004 |
Adem C, Soderberg CL, Hafner K, Reynolds C, Slezak JM, Sinclair CS, Sellers TA, Schaid DJ, Couch F, Hartmann LC, Jenkins RB. ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers. Genes, Chromosomes & Cancer. 41: 1-11. PMID 15236312 DOI: 10.1002/Gcc.20057 |
0.332 |
|
| 2004 |
Buckner JC, Aldape KD, Ballman K, Scheithauer BW, Burger PC, Giannini C, Schaefer PL, Jenkins RB, James CD. Immunohistochemical detection of EGFRvIII and prognostic significance in patients with malignant glioma enrolled in NCCTG clinical trials Journal of Clinical Oncology. 22: 1508-1508. DOI: 10.1200/Jco.2004.22.90140.1508 |
0.377 |
|
| 2004 |
Cairncross G, Seiferheld W, Shaw E, Jenkins R, Scheithauer B, Brachman D, Buckner J, Fink K, Souhami L, Curran W. An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94–02 Journal of Clinical Oncology. 22: 1500-1500. DOI: 10.1200/Jco.2004.22.90140.1500 |
0.356 |
|
| 2004 |
Dora CD, Kondo Y, Lan FX, Slezak JM, Bergstralh EJ, Jenkins RB, Sebo TJ. 588: Detection of Chromosome 8 Alterations in Paired Needle Biopsy and Prostatectomy Specimens Using Fluorescence In-Situ Hybridization Journal of Urology. 171: 156-156. DOI: 10.1016/S0022-5347(18)37850-9 |
0.304 |
|
| 2003 |
Adem C, Soderberg CL, Cunningham JM, Reynolds C, Sebo TJ, Thibodeau SN, Hartmann LC, Jenkins RB. Microsatellite instability in hereditary and sporadic breast cancers. International Journal of Cancer. 107: 580-2. PMID 14520695 DOI: 10.1002/Ijc.11442 |
0.319 |
|
| 2003 |
Kitange GJ, Templeton KL, Jenkins RB. Recent advances in the molecular genetics of primary gliomas. Current Opinion in Oncology. 15: 197-203. PMID 12778011 DOI: 10.1097/00001622-200305000-00003 |
0.348 |
|
| 2003 |
Buckner JC, Gesme D, O'Fallon JR, Hammack JE, Stafford S, Brown PD, Hawkins R, Scheithauer BW, Erickson BJ, Levitt R, Shaw EG, Jenkins R. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 251-5. PMID 12525516 DOI: 10.1200/Jco.2003.06.023 |
0.404 |
|
| 2002 |
Cheville JC, Tindall D, Boelter C, Jenkins R, Lohse CM, Pankratz VS, Sebo TJ, Davis B, Blute ML. Metastatic prostate carcinoma to bone : Clinical and pathologic features associated with cancer-specific survival Cancer. 95: 1028-1036. PMID 12209687 DOI: 10.1002/Cncr.10788 |
0.336 |
|
| 2002 |
Kitange GJ, Smith JS, Jenkins RB. Genetic alterations and chemotherapeutic response in human diffuse gliomas. Expert Review of Anticancer Therapy. 1: 595-605. PMID 12113092 DOI: 10.1586/14737140.1.4.595 |
0.334 |
|
| 2002 |
Tsuchiya N, Slezak JM, Lieber MM, Bergstralh EJ, Jenkins RB. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer. Genes, Chromosomes & Cancer. 34: 363-71. PMID 12112525 DOI: 10.1002/Gcc.10064 |
0.422 |
|
| 2002 |
Kuriyama H, Lamborn KR, O'Fallon JR, Iturria N, Sebo T, Schaefer PL, Scheithauer BW, Buckner JC, Kuriyama N, Jenkins RB, Israel MA. Prognostic significance of an apoptotic index and apoptosis/proliferation ratio for patients with high-grade astrocytomas. Neuro-Oncology. 4: 179-86. PMID 12084348 DOI: 10.1093/Neuonc/4.3.179 |
0.34 |
|
| 2002 |
Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN, Perez EA. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. Journal of the National Cancer Institute. 94: 855-7. PMID 12048274 DOI: 10.1093/Jnci/94.11.855 |
0.324 |
|
| 2002 |
Tsuchiya N, Kondo Y, Takahashi A, Pawar H, Qian J, Sato K, Lieber MM, Jenkins RB. Mapping and gene expression profile of the minimally overrepresented 8q24 region in prostate cancer. The American Journal of Pathology. 160: 1799-806. PMID 12000731 DOI: 10.1016/S0002-9440(10)61126-1 |
0.356 |
|
| 2002 |
Hartmann C, Johnk L, Sasaki H, Jenkins RB, Louis DN. Novel PLA2G4C polymorphism as a molecular diagnostic assay for 19q loss in human gliomas. Brain Pathology (Zurich, Switzerland). 12: 178-82. PMID 11958371 DOI: 10.1111/J.1750-3639.2002.Tb00432.X |
0.379 |
|
| 2002 |
Wei JL, Scheithauer BW, Smith JS, Jenkins RB, Passe SM, Arndt CA, Strome SE. Primary neuroblastoma of the maxillary sinus. International Journal of Pediatric Otorhinolaryngology. 63: 155-62. PMID 11955607 DOI: 10.1016/S0165-5876(01)00650-4 |
0.377 |
|
| 2002 |
Eley GD, Reiter JL, Pandita A, Park S, Jenkins RB, Maihle NJ, James CD. A chromosomal region 7p11.2 transcript map: its development and application to the study of EGFR amplicons in glioblastoma. Neuro-Oncology. 4: 86-94. PMID 11916499 DOI: 10.1093/Neuonc/4.2.86 |
0.345 |
|
| 2002 |
Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN, Wold LE. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clinic Proceedings. 77: 148-54. PMID 11838648 DOI: 10.4065/77.2.148 |
0.374 |
|
| 2002 |
Qian J, Hirasawa K, Bostwick DG, Bergstralh EJ, Slezak JM, Anderl KL, Borell TJ, Lieber MM, Jenkins RB. Loss of p53 and c-myc overrepresentation in stage T(2-3)N(1-3)M(0) prostate cancer are potential markers for cancer progression. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 15: 35-44. PMID 11796839 DOI: 10.1038/Modpathol.3880487 |
0.395 |
|
| 2002 |
Lindor NM, Dechet CB, Greene MH, Jenkins RB, Zincke MT, Weaver AL, Wilson M, Zincke H, Liu W. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population. Genetic Testing. 5: 101-6. PMID 11551094 DOI: 10.1089/109065701753145547 |
0.316 |
|
| 2001 |
Jenkins RB, Curran W, Scott CB, Cairncross G. Pilot evaluation of 1p and 19q deletions in anaplastic oligodendrogliomas collected by a national cooperative cancer treatment group. American Journal of Clinical Oncology. 24: 506-8. PMID 11586105 DOI: 10.1097/00000421-200110000-00018 |
0.385 |
|
| 2001 |
Burger PC, Minn AY, Smith JS, Borell TJ, Jedlicka AE, Huntley BK, Goldthwaite PT, Jenkins RB, Feuerstein BG. Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 14: 842-53. PMID 11557779 DOI: 10.1038/Modpathol.3880400 |
0.374 |
|
| 2001 |
Thomas C, Ely G, James CD, Jenkins R, Kastan M, Jedlicka A, Burger P, Wharen R. Glioblastoma-related gene mutations and over-expression of functional epidermal growth factor receptors in SKMG-3 glioma cells Acta Neuropathologica. 101: 605-615. PMID 11515790 DOI: 10.1007/S004010000332 |
0.335 |
|
| 2001 |
Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N, O'Fallon JR, Schaefer PL, Scheithauer BW, James CD, Buckner JC, Jenkins RB. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. Journal of the National Cancer Institute. 93: 1246-56. PMID 11504770 DOI: 10.1093/Jnci/93.16.1246 |
0.341 |
|
| 2001 |
Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: Apparent immunohistochemical false-positives do not get the message Journal of Clinical Oncology. 19: 2714-2721. PMID 11352964 DOI: 10.1200/Jco.2001.19.10.2714 |
0.331 |
|
| 2001 |
Nigro JM, Takahashi MA, Ginzinger DG, Law M, Passe S, Jenkins RB, Aldape K. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. The American Journal of Pathology. 158: 1253-62. PMID 11290543 DOI: 10.1016/S0002-9440(10)64076-X |
0.383 |
|
| 2001 |
Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA, King W. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. The Journal of Molecular Diagnostics : Jmd. 2: 116-23. PMID 11229514 DOI: 10.1016/S1525-1578(10)60625-3 |
0.332 |
|
| 2001 |
Gilhuis HJ, Anderl KL, Boerman RH, Jeuken JM, James CD, Raffel C, Scheithauer BW, Jenkins RB. Comparative genomic hybridization of medulloblastomas and clinical relevance: eleven new cases and a review of the literature. Clinical Neurology and Neurosurgery. 102: 203-209. PMID 11154805 DOI: 10.1016/S0303-8467(00)00112-8 |
0.409 |
|
| 2001 |
Jenkins R. Principles of Molecular Oncology The American Journal of Human Genetics. 68: 1068. DOI: 10.1086/319526 |
0.326 |
|
| 2001 |
Krishnadath KK, Wang KK, Buttar NS, Lutzke LS, Law M, Anderl KL, Jenkins RB, Liu W. Amplification of chromosome 20q13 region is associated with malignant progression of high grade dysplasia in Barrett's esophagus Gastroenterology. 120: A411. DOI: 10.1016/S0016-5085(08)82041-0 |
0.349 |
|
| 2000 |
Smith JS, Tachibana I, Lee HK, Qian J, Pohl U, Mohrenweiser HW, Borell TJ, Hosek SM, Soderberg CL, von Deimling A, Perry A, Scheithauer BW, Louis DN, Jenkins RB. Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. Genes, Chromosomes & Cancer. 29: 16-25. PMID 10918389 DOI: 10.1002/1098-2264(2000)9999:9999<::Aid-Gcc1007>3.3.Co;2-9 |
0.369 |
|
| 2000 |
Smith JS, Tachibana I, Lee HK, Qian J, Pohl U, Mohrenweiser HW, Borell TJ, Hosek SM, Soderberg CL, Deimling Av, Perry A, Scheithauer BW, Louis DN, Jenkins RB. Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers: Mapping of the Glioma 19q Tumor Suppressor Gene Genes, Chromosomes and Cancer. 29: 16-25. PMID 10918389 DOI: 10.1002/1098-2264(2000)9999:9999<::Aid-Gcc1007>3.0.Co;2-I |
0.368 |
|
| 2000 |
Smith JS, Wang XY, Qian J, Hosek SM, Scheithauer BW, Jenkins RB, James CD. Amplification of the platelet-derived growth factor receptor-a (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features Journal of Neuropathology and Experimental Neurology. 59: 495-503. PMID 10850862 DOI: 10.1093/Jnen/59.6.495 |
0.366 |
|
| 2000 |
Tachibana I, Smith JS, Sato K, Hosek SM, Kimmel DW, Jenkins RB. Investigation of germline PTEN, p53, p16(INK4A)/p14(ARF), and CDK4 alterations in familial glioma. American Journal of Medical Genetics. 92: 136-41. PMID 10797439 DOI: 10.1002/(Sici)1096-8628(20000515)92:2<136::Aid-Ajmg11>3.0.Co;2-S |
0.36 |
|
| 2000 |
Binzak BA, Vockley JG, Jenkins RB, Vockley J. Structure and analysis of the human dimethylglycine dehydrogenase gene Molecular Genetics and Metabolism. 69: 181-187. PMID 10767172 DOI: 10.1006/Mgme.2000.2980 |
0.303 |
|
| 2000 |
Smith JS, Tachibana I, Pohl U, Lee HK, Thanarajasingam U, Portier BP, Ueki K, Ramaswamy S, Billings SJ, Mohrenweiser HW, Louis DN, Jenkins RB. A transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics. 64: 44-50. PMID 10708517 DOI: 10.1006/Geno.1999.6101 |
0.362 |
|
| 2000 |
Smith JS, Jenkins RB. Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications. Frontiers in Bioscience : a Journal and Virtual Library. 5: D213-31. PMID 10702383 DOI: 10.2741/Smith |
0.408 |
|
| 2000 |
Pohl U, Smith JS, Tachibana I, Ueki K, Lee HK, Ramaswamy S, Wu Q, Mohrenweiser HW, Jenkins RB, Louis DN. EHD2, EHD3, and EHD4 encode novel members of a highly conserved family of EH domain-containing proteins. Genomics. 63: 255-62. PMID 10673336 DOI: 10.1006/Geno.1999.6087 |
0.357 |
|
| 2000 |
Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, Kimmel D, Yates A, Burger PC, Scheithauer BW, Jenkins RB. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 18: 636-45. PMID 10653879 DOI: 10.1200/Jco.2000.18.3.636 |
0.414 |
|
| 2000 |
Reiter RE, Sato I, Thomas G, Qian J, Gu Z, Watabe T, Loda M, Jenkins RB. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes, Chromosomes & Cancer. 27: 95-103. PMID 10564591 DOI: 10.1002/(Sici)1098-2264(200001)27:1<95::Aid-Gcc12>3.0.Co;2-3 |
0.395 |
|
| 2000 |
Wang L, Darling J, Zhang JS, Liu W, Qian J, Bostwick D, Hartmann L, Jenkins R, Bardenhauer W, Schutte J, Opalka B, Smith DI. Loss of expression of the DRR 1 gene at chromosomal segment 3p21.1 in renal cell carcinoma. Genes, Chromosomes & Cancer. 27: 1-10. PMID 10564580 DOI: 10.1002/(Sici)1098-2264(200001)27:1<1::Aid-Gcc1>3.0.Co;2-6 |
0.358 |
|
| 2000 |
HALLING KC, KING W, SOKOLOVA IA, MEYER RG, BURKHARDT HM, HALLING AC, CHEVILLE JC, SEBO TJ, RAMAKUMAR S, STEWART CS, PANKRATZ S, O’KANE DJ, SEELIG SA, LIEBER MM, JENKINS RB. A COMPARISON OF CYTOLOGY AND FLUORESCENCE IN SITU HYBRIDIZATION FOR THE DETECTION OF UROTHELIAL CARCINOMA Journal of Urology. 164: 1768-1775. DOI: 10.1016/S0022-5347(05)67104-2 |
0.354 |
|
| 1999 |
Brown JA, Slezak JM, Lieber MM, Jenkins RB. Fluorescence in situ hybridization aneuploidy as a predictor of clinical disease recurrence and prostate-specific antigen level 3 years after radical prostatectomy. Mayo Clinic Proceedings. 74: 1214-20. PMID 10593349 DOI: 10.4065/74.12.1214 |
0.407 |
|
| 1999 |
Perry A, Anderl K, Borell TJ, Kimmel DW, Wang CH, O'Fallon JR, Feuerstein BG, Scheithauer BW, Jenkins RB. Detection of p16, RB, CDK4, and p53 gene deletion and amplification by fluorescence in situ hybridization in 96 gliomas American Journal of Clinical Pathology. 112: 801-809. PMID 10587703 DOI: 10.1093/Ajcp/112.6.801 |
0.37 |
|
| 1999 |
Peters N, Smith JS, Tachibana I, Lee HK, Pohl U, Portier BP, Louis DN, Jenkins RB. The human glia maturation factor-gamma gene: genomic structure and mutation analysis in gliomas with chromosome 19q loss. Neurogenetics. 2: 163-6. PMID 10541589 DOI: 10.1007/S100480050077 |
0.374 |
|
| 1999 |
Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ, Jenkins RB. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. Journal of the National Cancer Institute. 91: 1574-80. PMID 10491435 DOI: 10.1093/Jnci/91.18.1574 |
0.391 |
|
| 1999 |
Shridhar V, Staub J, Huntley B, Cliby W, Jenkins R, Pass HI, Hartmann L, Smith DI. A novel region of deletion on chromosome 6q23.3 spanning less than 500 Kb in high grade invasive epithelial ovarian cancer Oncogene. 18: 3913-3918. PMID 10445856 DOI: 10.1038/Sj.Onc.1202756 |
0.369 |
|
| 1999 |
Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G, Hosek SM, Kimmel D, O'Fallon J, Yates A, Feuerstein BG, Burger PC, Scheithauer BW, Jenkins RB. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene. 18: 4144-52. PMID 10435596 DOI: 10.1038/Sj.Onc.1202759 |
0.384 |
|
| 1999 |
James CD, Galanis E, Frederick L, Kimmel DW, Cunningham JM, Atherton-Skaff PJ, O'Fallon JR, Jenkins RB, Buckner JC, Hunter SB, Olson JJ, Scheithauer BW. Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation. International Journal of Oncology. 15: 547-53. PMID 10427138 DOI: 10.3892/Ijo.15.3.547 |
0.374 |
|
| 1999 |
Smith JS, Tachibana I, Allen C, Chiappa SA, Lee HK, McIver B, Jenkins RB, Raffel C. Cloning of a human ortholog (RPH3AL) of (RNO)Rph3al from a candidate 17p13.3 medulloblastoma tumor suppressor locus. Genomics. 59: 97-101. PMID 10395805 DOI: 10.1006/Geno.1999.5864 |
0.382 |
|
| 1999 |
Qian J, Jenkins RB, Bostwick DG. Genetic and chromosomal alterations in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization. European Urology. 35: 479-83. PMID 10325509 DOI: 10.1159/000019883 |
0.329 |
|
| 1999 |
Yokomizo A, Mai M, Bostwick DG, Tindall DJ, Qian J, Cheng L, Jenkins RB, Smith DI, Liu W. Mutation and expression analysis of the p73 gene in prostate cancer. The Prostate. 39: 94-100. PMID 10221564 DOI: 10.1002/(Sici)1097-0045(19990501)39:2<94::Aid-Pros3>3.0.Co;2-W |
0.364 |
|
| 1999 |
Villeneuve JB, Silverman MB, Alderete B, Cliby WA, Li H, Croghan GA, Podratz KC, Jenkins RB. Loss of markers linked to BRCA1 precedes loss at important cell cycle regulatory genes in epithelial ovarian cancer. Genes, Chromosomes & Cancer. 25: 65-9. PMID 10221342 DOI: 10.1002/(Sici)1098-2264(199905)25:1<65::Aid-Gcc10>3.0.Co;2-F |
0.382 |
|
| 1999 |
Hogan WJ, Tefferi A, Borell TJ, Jenkins R, Li CY, Witzig TE. Prognostic relevance of monosomy at the 13q14 locus detected by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia. Cancer Genetics and Cytogenetics. 110: 77-81. PMID 10214353 DOI: 10.1016/S0165-4608(98)00207-6 |
0.367 |
|
| 1999 |
Huang H, Reed CP, Mordi A, Lomberk G, Wang L, Shridhar V, Hartmann L, Jenkins R, Smith DI. Frequent deletions within FRA7G at 7q31.2 in invasive epithelial ovarian cancer Genes, Chromosomes and Cancer. 24: 48-55. PMID 9892108 DOI: 10.1002/(Sici)1098-2264(199901)24:1<48::Aid-Gcc7>3.0.Co;2-V |
0.383 |
|
| 1999 |
Perry A, Smith JS, Borell TJ, Lee HK, OʼFallon J, Kimmel SD, Burger PC, Scheithauer BW, Jenkins RB. ALTERATIONS OF CHROMOSOME ARMS 1p AND 19q AS PREDICTORS OF SURVIVAL IN DIFFUSE GLIOMAS Journal of Neuropathology and Experimental Neurology. 58: 512. DOI: 10.1097/00005072-199905000-00024 |
0.349 |
|
| 1998 |
Galanis E, Buckner JC, Dinapoli RP, Scheithauer BW, Jenkins RB, Wang CH, O'Fallon JR, Farr G. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. Journal of Neurosurgery. 89: 425-30. PMID 9724117 DOI: 10.3171/Jns.1998.89.3.0425 |
0.325 |
|
| 1998 |
Yokomizo A, Tindall DJ, Hartmann L, Jenkins RB, Smith DI, Liu W. Mutation analysis of the putative tumor suppressor PTEN/MMAC1 in human ovarian cancer. International Journal of Oncology. 13: 101-5. PMID 9625810 DOI: 10.3892/Ijo.13.1.101 |
0.362 |
|
| 1998 |
Jenkins R, Takahashi S, DeLacey K, Bergstralh E, Lieber M. Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0M0 prostate cancer. Genes, Chromosomes & Cancer. 21: 131-43. PMID 9491325 DOI: 10.1002/(Sici)1098-2264(199802)21:2<131::Aid-Gcc9>3.0.Co;2-1 |
0.408 |
|
| 1998 |
Nacheva EP, Grace CD, Bittner M, Ledbetter DH, Jenkins RB, Green AR. Comparative genomic hybridization: a comparison with molecular and cytogenetic analysis. Cancer Genetics and Cytogenetics. 100: 93-105. PMID 9428351 DOI: 10.1016/S0165-4608(97)00021-6 |
0.353 |
|
| 1998 |
Galanis E, Buckner J, Kimmel D, Jenkins R, Alderete B, O'Fallon J, Wang CH, Scheithauer BW, James CD. Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. International Journal of Oncology. 13: 717-724. DOI: 10.3892/Ijo.13.4.717 |
0.394 |
|
| 1997 |
Perry A, Nobori T, Ru N, Anderl K, Borell TJ, Mohapatra G, Feuerstein BG, Jenkins RB, Carson DA. Detection of p16 gene deletions in gliomas: A comparison of fluorescence in situ hybridization (FISH) versus quantitative PCR Journal of Neuropathology and Experimental Neurology. 56: 999-1008. PMID 9291941 DOI: 10.1097/00005072-199709000-00005 |
0.368 |
|
| 1997 |
Giannini C, Scheithauer BW, Jenkins RB, Erlandson RA, Perry A, Borell TJ, Hoda RS, Woodruff JM. Soft-tissue perineurioma. Evidence for an abnormality of chromosome 22, criteria for diagnosis, and review of the literature. The American Journal of Surgical Pathology. 21: 164-73. PMID 9042282 DOI: 10.1097/00000478-199702000-00005 |
0.358 |
|
| 1997 |
Cunningham JM, Kimmel DW, Scheithauer BW, O'Fallon JR, Novotny PJ, Jenkins RB. Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. Journal of Neurosurgery. 86: 121-30. PMID 8988090 DOI: 10.3171/Jns.1997.86.1.0121 |
0.389 |
|
| 1997 |
Perry A, Nobori T, Rul N, Anderl K, Borell T, Mohapatra G, Feuerstein B, Jenkins R, Carson D. Detection of p16 gene deletions in gliomas: Fish vs. quantitative PCR Cancer Genetics and Cytogenetics. 98: 163. DOI: 10.1016/S0165-4608(97)90295-8 |
0.319 |
|
| 1997 |
Jenkins R, Qian J, Lee H, Hirasawa K, Lieber M. Molecular cytogenetic analyses of 7Q31 in prostate cancer Cancer Genetics and Cytogenetics. 98: 152. DOI: 10.1016/S0165-4608(97)90253-3 |
0.326 |
|
| 1997 |
Gburek BM, Kollmorgen TA, Qian J, D'Souza-Gburek SM, Lieber MM, Jenkins RB. Chromosomal Anomalies in Stage D1 Prostate Adenocarcinoma Primary Tumors and Lymph Node Metastases Detected by Fluorescence in Situ Hybridization Journal of Urology. 157: 223-227. DOI: 10.1016/S0022-5347(01)65331-X |
0.383 |
|
| 1997 |
Brown JA, Anderl KL, Borell TJ, Qian J, Bostwick DG, Jenkins RB. Simultaneous Chromosome 7 and 17 Gain and Sex Chromosome Loss Provide Evidence that Renal Metanephric Adenoma is Related to Papillary Renal Cell Carcinoma Journal of Urology. 158: 370-374. DOI: 10.1016/S0022-5347(01)64482-3 |
0.34 |
|
| 1996 |
Boerman RH, Anderl K, Herath J, Borell T, Johnson N, Schaeffer-Klein J, Kirchhof A, Raap AK, Scheithauer BW, Jenkins RB. The glial and mesenchymal elements of gliosarcomas share similar genetic alterations. Journal of Neuropathology and Experimental Neurology. 55: 973-81. PMID 8800093 DOI: 10.1097/00005072-199609000-00004 |
0.371 |
|
| 1996 |
Lindor NM, Karnes PS, Michels VV, Dewald GW, Goerss J, Jalal S, Jenkins RB, Vockley G, Thibodeau SN. Uniparental disomy in congenital disorders: a prospective study. American Journal of Medical Genetics. 58: 143-6. PMID 8533805 DOI: 10.1002/Ajmg.1320580210 |
0.32 |
|
| 1996 |
Brown JA, Takahashi S, Alcaraz A, Borell TJ, Anderl KL, Qian J, Persons DL, Bostwick DG, Lieber MM, Jenkins RB. Fluorescence In Situ Hybridization Analysis of Renal Oncocytoma Reveals Frequent Loss of Chromosomes Y and 1 Journal of Urology. 156: 31-35. DOI: 10.1016/S0022-5347(01)65929-9 |
0.329 |
|
| 1995 |
Dalrymple SJ, Jenkins RB. Molecular genetics of astrocytomas and meningiomas. Current Opinion in Neurology. 7: 477-83. PMID 7866578 DOI: 10.1097/00019052-199412000-00002 |
0.392 |
|
| 1995 |
Persons DL, Hartmann LC, Herath JF, Keeney GL, Jenkins RB. Fluorescence in situ hybridization analysis of trisomy 12 in ovarian tumors. American Journal of Clinical Pathology. 102: 775-9. PMID 7801890 DOI: 10.1093/Ajcp/102.6.775 |
0.359 |
|
| 1995 |
Emory TS, Scheithauer BW, Hirose T, Wood M, Onofrio BM, Jenkins RB. Intraneural perineurioma. A clonal neoplasm associated with abnormalities of chromosome 22. American Journal of Clinical Pathology. 103: 696-704. PMID 7785653 DOI: 10.1093/Ajcp/103.6.696 |
0.347 |
|
| 1995 |
Dalrymple SJ, Herath JF, Ritland SR, Moertel CA, Jenkins RB. Use of fluorescence in situ hybridization to detect loss of chromosome 10 in astrocytomas. Journal of Neurosurgery. 83: 316-23. PMID 7616278 DOI: 10.3171/Jns.1995.83.2.0316 |
0.384 |
|
| 1995 |
Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nature Genetics. 11: 210-212. PMID 7550353 DOI: 10.1038/Ng1095-210 |
0.348 |
|
| 1995 |
Cher ML, MacGrogan D, Bookstein R, Brown JA, Jenkins RB, Jensen RH. Comparative genomic hybridization, allelic imbalance, and fluorescence in situ hybridization on chromosome 8 in prostate cancer. Genes, Chromosomes & Cancer. 11: 153-62. PMID 7530484 DOI: 10.1002/Gcc.2870110304 |
0.415 |
|
| 1995 |
Witzig TE, Borell TJ, Herath JF, Tefferi A, Li CY, Jenkins RB. Detection of trisomy 12 by FISH in untreated B-chronic lymphocytic leukemia: correlation with stage and CD20 antigen expression intensity. Leukemia & Lymphoma. 14: 447-51. PMID 7529078 DOI: 10.3109/10428199409049702 |
0.321 |
|
| 1995 |
Cheng TM, Ganju V, Ritland SR, Sarkar G, Jenkins RB. [14] Analysis of p53 mutations in human gliomas by RNA single-strand conformational polymorphism Methods in Neurosciences. 26: 210-224. DOI: 10.1016/S1043-9471(06)80092-3 |
0.374 |
|
| 1994 |
Tomlinson FH, Jenkins RB, Scheithauer BW, Keelan PA, Ritland S, Parisi JE, Cunningham J, Olsen KD. Aggressive medulloblastoma with high-level N-myc amplification. Mayo Clinic Proceedings. 69: 359-65. PMID 8170180 DOI: 10.1016/S0025-6196(12)62221-6 |
0.392 |
|
| 1994 |
Herath SE, Stalboerger PG, Dahl RJ, Parisi JE, Jenkins RB. Cytogenetic studies of four hemangiopericytomas. Cancer Genetics and Cytogenetics. 72: 137-40. PMID 8143272 DOI: 10.1016/0165-4608(94)90129-5 |
0.378 |
|
| 1994 |
Dalrymple SJ, Herath JF, Borell TJ, Moertel CA, Jenkins RB. Correlation of cytogenetic and fluorescence in situ hybridization (FISH) studies in normal and gliotic brain. Journal of Neuropathology and Experimental Neurology. 53: 448-56. PMID 8083688 DOI: 10.1097/00005072-199409000-00004 |
0.331 |
|
| 1994 |
Brown JA, Alcaraz A, Takahashi S, Persons DL, Lieber MM, Jenkins RB. Chromosomal aneusomies detected by fluorescent in situ hybridization analysis in clinically localized prostate carcinoma. The Journal of Urology. 152: 1157-62. PMID 8072085 DOI: 10.1016/S0022-5347(17)32527-2 |
0.376 |
|
| 1994 |
Ganju V, Jenkins RB, O'Fallon JR, Scheithauer BW, Ransom DT, Katzmann JA, Kimmel DW. Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers. Cancer. 74: 920-7. PMID 8039120 DOI: 10.1002/1097-0142(19940801)74:3<920::Aid-Cncr2820740320>3.0.Co;2-4 |
0.314 |
|
| 1994 |
Persons DL, Takai K, Gibney DJ, Katzmann JA, Lieber MM, Jenkins RB. Comparison of fluorescence in situ hybridization with flow cytometry and static image analysis in ploidy analysis of paraffin-embedded prostate adenocarcinoma. Human Pathology. 25: 678-83. PMID 8026827 DOI: 10.1016/0046-8177(94)90301-8 |
0.321 |
|
| 1993 |
Persons DL, Gibney DJ, Katzmann JA, Lieber MM, Farrow GM, Jenkins RB. Use of fluorescent in situ hybridization for deoxyribonucleic acid ploidy analysis of prostatic adenocarcinoma. The Journal of Urology. 150: 120-5. PMID 8510232 DOI: 10.1016/S0022-5347(17)35412-5 |
0.339 |
|
| 1993 |
Moertel CA, Dahl RJ, Stalboerger PG, Kimmel DW, Scheithauer BW, Jenkins RB. Gliosis specimens contain clonal cytogenetic abnormalities. Cancer Genetics and Cytogenetics. 67: 21-7. PMID 8504395 DOI: 10.1016/0165-4608(93)90039-O |
0.359 |
|
| 1993 |
Noël P, Tefferi A, Pierre RV, Jenkins RB, Dewald GW. Karyotypic analysis in primary myelodysplastic syndromes. Blood Reviews. 7: 10-8. PMID 8467227 DOI: 10.1016/0268-960X(93)90019-Z |
0.325 |
|
| 1993 |
Cliby W, Sarkar G, Ritland SR, Hartmann L, Podratz KC, Jenkins RB. Absence of prohibitin gene mutations in human epithelial ovarian tumors. Gynecologic Oncology. 50: 34-7. PMID 8349162 DOI: 10.1006/Gyno.1993.1160 |
0.375 |
|
| 1993 |
Jenkins RB, Bartelt D, Stalboerger P, Persons D, Dahl RJ, Podratz K, Keeney G, Hartmann L. Cytogenetic studies of epithelial ovarian carcinoma. Cancer Genetics and Cytogenetics. 71: 76-86. PMID 8275457 DOI: 10.1016/0165-4608(93)90205-Z |
0.395 |
|
| 1993 |
Menke DM, Colon-Otero G, Cockerill KJ, Jenkins RB, Noel P, Pierre RV. Refractory thrombocytopenia. A myelodysplastic syndrome that may mimic immune thrombocytopenic purpura. American Journal of Clinical Pathology. 98: 502-10. PMID 1485603 DOI: 10.1093/Ajcp/98.5.502 |
0.321 |
|
| 1993 |
Ransom DT, Ritland SR, Kimmel DW, Moertel CA, Dahl RJ, Scheithauer BW, Kelly PJ, Jenkins RB. Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas. Genes, Chromosomes & Cancer. 5: 348-56. PMID 1283324 DOI: 10.1002/Gcc.2870050411 |
0.34 |
|
| 1992 |
Crotty TB, Lawrence KM, Moertel CA, Bartelt DH, Batts KP, Dewald GW, Farrow GM, Jenkins RB. Cytogenetic analysis of six renal oncocytomas and a chromophobe cell renal carcinoma. Evidence that -Y, -1 may be a characteristic anomaly in renal oncocytomas. Cancer Genetics and Cytogenetics. 61: 61-6. PMID 1638482 DOI: 10.1016/0165-4608(92)90372-F |
0.31 |
|
| 1992 |
Kimmel DW, O'Fallon JR, Scheithauer BW, Kelly PJ, Dewald GW, Jenkins RB. Prognostic value of cytogenetic analysis in human cerebral astrocytomas. Annals of Neurology. 31: 534-42. PMID 1596090 DOI: 10.1002/Ana.410310512 |
0.386 |
|
| 1992 |
Lindor NM, Ney JA, Gaffey TA, Jenkins RB, Thibodeau SN, Dewald GW. A genetic review of complete and partial hydatidiform moles and nonmolar triploidy. Mayo Clinic Proceedings. 67: 791-9. PMID 1434919 DOI: 10.1016/S0025-6196(12)60805-2 |
0.31 |
|
| 1992 |
Kraker WJ, Borell TJ, Schad CR, Pennington MJ, Karnes PS, Dewald GW, Jenkins RB. Fluorescent in situ hybridization: use of whole chromosome paint probes to identify unbalanced chromosome translocations. Mayo Clinic Proceedings. 67: 658-62. PMID 1434900 DOI: 10.1016/S0025-6196(12)60721-6 |
0.321 |
|
| 1992 |
Ransom DT, Ritland SR, Moertel CA, Dahl RJ, O'Fallon JR, Scheithauer BW, Kimmel DW, Kelly PJ, Olopade OI, Diaz MO, Jenkins RB. Correlation of cytogenetic analysis and loss of heterozygosity studies in human diffuse astrocytomas and mixed oligo-astrocytomas Genes Chromosomes and Cancer. 5: 357-374. PMID 1283325 DOI: 10.1002/Gcc.2870050412 |
0.407 |
|
| 1992 |
Jenkins R, Beau ML, Kraker W, Borell T, Stalboerger P, Davis E, Penland L, Fernald A, Espinosa Rd, Schaid D. Fluorescence in situ hybridization: a sensitive method for trisomy 8 detection in bone marrow specimens. Blood. 79: 3307-3315. DOI: 10.1182/Blood.V79.12.3307.3307 |
0.315 |
|
| 1991 |
Schad CR, Kraker WJ, Jalal SM, Tallman MS, Londer HN, Cook LP, Jenkins RB. Use of fluorescent in situ hybridization for marker chromosome identification in congenital and neoplastic disorders. American Journal of Clinical Pathology. 96: 203-10. PMID 1862775 DOI: 10.1093/Ajcp/96.2.203 |
0.329 |
|
| 1991 |
Schwartz HS, Butler MG, Jenkins RB, Miller DA, Moses HL. Telomeric associations and consistent growth factor overexpression detected in giant cell tumor of bone. Cancer Genetics and Cytogenetics. 56: 263-76. PMID 1756472 DOI: 10.1016/0165-4608(91)90179-X |
0.354 |
|
| 1991 |
Herrmann MA, Hay ID, Bartelt DH, Spurbeck JL, Dahl RJ, Grant CS, Jenkins RB. Cytogenetics of six follicular thyroid adenomas including a case report of an oxyphil variant with t(8;14)(q13;q24.1) Cancer Genetics and Cytogenetics. 56: 231-235. PMID 1756468 DOI: 10.1016/0165-4608(91)90175-T |
0.32 |
|
| 1990 |
Jenkins RB, Hay ID, Herath JF, Schultz CG, Spurbeck JL, Grant CS, Goellner JR, Dewald GW. Frequent occurrence of cytogenetic abnormalities in sporadic nonmedullary thyroid carcinoma. Cancer. 66: 1213-20. PMID 2400971 DOI: 10.1002/1097-0142(19900915)66:6<1213::Aid-Cncr2820660622>3.0.Co;2-9 |
0.356 |
|
| 1989 |
Jenkins RB, Kimmel DW, Moertel CA, Schultz CG, Scheithauer BW, Kelly PJ, Dewald GW. A cytogenetic study of 53 human gliomas. Cancer Genetics and Cytogenetics. 39: 253-79. PMID 2752377 DOI: 10.1016/0165-4608(89)90192-1 |
0.384 |
|
| 1989 |
Jenkins RB, Tefferi A, Solberg LA, Dewald GW. Acute leukemia with abnormal thrombopoiesis and inversions of chromosome 3. Cancer Genetics and Cytogenetics. 39: 167-79. PMID 2752370 DOI: 10.1016/0165-4608(89)90182-9 |
0.348 |
|
| 1989 |
Schwartz HS, Jenkins RB, Dahl RJ, Dewald Gw. Cytogenetic analyses on giant-cell tumors of bone. Clinical Orthopaedics and Related Research. 250-260. DOI: 10.1097/00003086-198903000-00033 |
0.36 |
|
| Show low-probability matches. |